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Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. 
Many sufferers never return to their pre-injury level of function and have life-long 
health and socioeconomic problems that limit their daily activities. In the last two 
decades there has been renewed interest in whether post-TBI anterior pituitary 
dysfunction (PTPD) contributes to morbidity.  
 
The PhD focuses on patients with mild TBI (mTBI). My aims are to explore the 
scientific evidence for PTPD including its prevalence in the TBI population and how it 
is currently managed by Neurosurgeons in Great Britain and Ireland. I also 
performed a prospective, feasibility study to determine if a larger study of the acute 
and long-term effects of isolated mTBI on anterior pituitary function was deliverable. 
Pilot data are presented in this thesis.  
 
Our systematic review demonstrated that PTPD occurs in one-third of patients 12 
months after TBI and we found disparities in surveillance practices across the UK 
and Ireland. We demonstrated in our feasibility study that 44% of patients have 
abnormal anterior pituitary hormone activity in the first 7 days following mTBI and 
20% of patients who were followed up at 6 months had evidence of PTPD. We found 
no evidence that PTPD occurs as a result of structural damage to the anterior 
pituitary gland, suggesting other, yet to be determined factors play a role. A large, 
prospective, multi-centre study is needed to better understand the pathophysiology 
and incidence of PTPD. 
 
Lay Summary 
In the past 4 decades, there have been great advances in the way we treat people 
that suffer traumatic brain injuries (TBIs). These advances mean that more people 
are surviving after a TBI. The most common type of TBI is the least severe for, mild 
TBI or mTBI. MTBI is the focus of this thesis. Many survivors of mTBI do not return 
to the level of function they were at before the TBI. For example, many people are 
unable to do the type of work and social activities they did before the TBI because of 
the disabilities they sustained. Many mTBI sufferers may have structural damage to 
their brains that explain their disability, but others do not have any obvious structural 
problems to explain their ongoing symptoms and disabilities. 
 
In the last 2 decades, there has been resurgence in the theory that some people 
may damage their anterior pituitary gland during their initial injury and that this may 
account for at least some of the symptoms in patients that have ongoing problems. 
The anterior pituitary is the front part of a pea-sized organ that sits under the brain 
and is one of the most important organs for homeostasis (balancing hormones in the 
body). The hormones secreted by the anterior pituitary control a range of functions 
from ability to concentrate and libido to metabolic rate and energy levels. Problems 
with anterior pituitary hormone secretion can be treated with replacement hormones. 
This is significant in the management of patients following TBI as treatments are 
readily available. 
 
There were 3 main aims in this project. The first of which was to determine how 
common anterior pituitary dysfunction is after TBI. I did this by performing a review of 
the literature. Secondly, I designed a study to prospectively research the incidence of 
anterior pituitary dysfunction in patients with mild forms of TBI. Finally, I used the 
study design to conduct a feasibility study to determine whether the design protocol 
is workable. The results of this feasibility study gave information about how 
commonly anterior pituitary dysfunction occurs in patients with mild forms of TBI. 
 
I found that one-third of patients develop anterior pituitary dysfunction when they are 
tested one year or more following TBI. I also found that UK and Irish neurosurgeons 
have very different ways of monitoring patients because of the lack of guidelines. 
Finally, I found that the protocol I designed was feasible and the results showed that 
one third of patients with mild forms of TBI developed anterior pituitary gland 
dysfunction when tested at 6 months even though there was no structural damage to 
their pituitary gland. This shows that anterior pituitary problems are common after 
mTBI and a large study is now needed to work out how common it is and exactly 
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1.1. Traumatic brain injury definition 
Traumatic brain injury (TBI) is defined as an alteration in brain function caused by an 
external force. It is a major public health issue that affects between 150 and 300 
people per 100000 in Europe, 229 per 100000 in England and in Scotland, 
approximately 65 people per year die from TBI1 2 3. TBI is a leading cause of death 
and disability among young people and has significant socio-economic 
consequences including unemployment and loss of independence4. The disease 
burden is significant.  
 
According to the demographics and clinical assessment working group of the 
International and Interagency Initiative toward Common Data Elements for Research 
on Traumatic Brain Injury and Psychological Health5, “alteration in brain function” 
can be one (or more) of the following: 
• Any period of loss of or decreased consciousness 
• Any loss of memory for events immediately before or after the injury 
• Neurological deficits 
• Alteration in mental state at the time of injury. This includes confusion, 
disorientation or slow thinking 
 
The severity of TBI is assessed by the post-resuscitative neurological status of the 
patient. The most commonly used assessment of neurological status is the Glasgow 
Coma Scale (GCS), which consists of the sum score of three components: 
assessments of patients’ eye opening, verbal and motor responses in relation to 
verbal or painful stimuli (figure 1).The minimum GCS score possible is 3 and the 
maximum is 15. A post-resuscitative GCS of 13-15 is usually considered a mild TBI, 
a GCS score of 9-12 is considered moderate and a GCS score of 3 to 8 is 
considered a severe TBI. 
 
Mild TBI (mTBI) constitutes approximately 80% of all TBIs and is the focus of this 
PhD thesis. It was once thought that there were no long term consequences for most 
patients that suffer a mTBI. However, we now know that approximately 15% of these 
patients develop persisting physical, cognitive and emotional symptoms. Headaches 
are the most common, however other symptoms include fatigue, concentration and 
memory problems, irritability and anxiety. These symptoms are often non-specific 
and can persist for months or years following mTBI. They are often diagnosed under 
the umbrella term post-concussion syndrome (PCS). 
 
PCS describes a cluster of symptoms that occur for longer than a few days (usually 
2 weeks) following mTBI. These include headache, dizziness, irritability, difficulty 
concentrating, memory problems, fatigue, visual disturbances, sensitivity to noise, 
judgment problems, depression, and anxiety. These symptoms can also occur 
following all severities of TBI but only persist in a small number of patients.There is 
ongoing debate as to whether the symptoms are non-organic (psychological) or 
organic (neurological). One potential organic cause for PCS is post-TBI pituitary 
dysfunction (PTPD), specifically anterior pituitary dysfunction. In the last two 
decades, there have been several reports that PTPD occurs in a significant 
proportion of cohorts that are followed up long term. Two meta-analyses have both 
concluded that approximately one-third of patients develop PTPD after TBI. The 
symptoms of anterior pituitary dysfunction overlap those of PCS. It is therefore 
conceivable that some patients diagnosed with PCS have neuroendocrine 
dysfunction. It has been hypothesised that up to 7% of all cases of hypopituitarism 
may be related to TBI6. 
 
  
There are a number of hypotheses about how pituitary function may become 
dysfunctional following TBI. Firstly, the neuroendocrine theory suggests that PTPD 
may be a maladaptive physiological process: the hypothalamo-pituitary-adrenal 
(HPA) axis is activated following TBI (and other stressors) and leads both to an 
increase in serum cortisol and disruption of its usual diurnal rhythm. 
Similarly, hyperprolactaemia may occur. These acute responses, which are often 
accompanied by suppression in the other hypothalamic-anterior pituitary (HP) axes, 
usually normalise over time. PTPD could be due to an abnormally sustained 
response of the pituitary gland to TBI.  
 
A second theory suggests that the pituitary gland’s location within the sella turcica, 
makes it susceptible to injury either at the time of TBI through direct impact on the 
bony sella or through compression during subsequent oedema. Furthermore, the 
anterior pituitary gland is supplied by branches of the hypophyseal portal vessels 
which, according to the vascular theory of PTPD, are also vulnerable to shearing 
during the acceleration and deceleration of the brain at the time of TBI7.  There have 
been numerous radiological and histopathological reports of damage to the pituitary 
and hypophyseal vessels in patients who succumb from TBI.8 9 10. It seems likely that 
this mechanism of PTPD is more significant in moderate and severe TBIs 
than in mTBI. 
 
 
Finally, the autoimmune theory, postulates that circulating anti-hypothalamic 
antibodies (AHAs) and antipituitary antibodies (APAs), develop following TBI and 
may play a role in the pathogenesis of PTPD. Tanriverdi and colleagues found APAs 
in 45% of TBI patients followed up over 3 years compared to none in age- and sex-
matched control groups and found that patients with APAs were more likely to have 
PTPD11. However these findings are yet to be repeated by other researchers.   
 
PTPD is potentially reversible with hormone replacement and it is therefore important 
that affected patients are identified and treated appropriately. Testing all TBI 
sufferers is not feasible because of the financial and time costs involved. The 
function of the anterior pituitary gland is assessed by checking the serum 
concentrations of the efferent hormones of the HP axes which are circulating growth 
hormone, thyroid hormones, cortisol, prolactin and the sex hormones testosterone, 
follicle stimulating hormone and leutinising hormone. Whilst the circulating 
concentrations of most of these hormones are closely regulated within a narrow 
range, cortisol and growth hormone concentrations vary throughout the day and 
therefore the function of the hypothalamo-pituitary somatotrophic (HPS) and the HPA 
axes are best checked with stimulation tests where hormone levels (cortisol or 
growth hormone) are checked prior to, and sometime after intravenous 
administration of agents that stimulate their release.  
 
Assessing these two axes is therefore invasive, time-consuming and expensive. 
Less invasive methods for assessing adrenal function include single measurement 
serum cortisol assays and salivary cortisol. However, serum cortisol is the protein 
bound hormone rather than the free hormone. As a result its concentration depends 
on transport proteins like albumin and cortisol-binding globulin, the concentrations of 
which can be variable. By contrast, early morning salivary cortisol is a non-invasive 
method of assessing adrenal function, which unlike serum cortisol is not influenced 
by binding proteins and therefore is more reflective of the bioactive free hormone. 
However, its accuracy in diagnosing adrenal insufficiency remains to be fully 
established. Similarly, the value of serum insulin-like growth factor-1 (IGF-1) and IGF 
binding protein-3 (IGFBP-3) as less invasive methods of diagnosing growth hormone 
deficiency is contentious as they can be normal in patients with undisputed growth 
hormone deficiency12.  
 
Most of the evidence on PTPD comes from studies on patients with moderate and 
severe TBI. My PhD aims to determine the relationship between mTBI and PTPD. 
These patients are usually managed by non-specialist and are therefore rarely 
followed up and the outcomes from these patients are less clear. The current 
guidelines recommend that patients with mTBI should be screened if they present 
with symptoms of hypopituitarism. 
 
1.2. Aims of PhD 
The main aims of my PhD are:  
 
1. Determine the prevalence of PTPD 12 months or more following TBI as 
described in contemporary literature 
2. Determine the current surveillance practices for PTPD in the UK and Ireland 
3. Design a study protocol to determine the prevalence of  PTPD in patients with 
mTBI 
4. Perform a feasibility study aimed at determining the prevalence of PTPD in 
patients with mTBI 
 
1.3.  Hypothesis 
Some patients with mild TBI (mTBI) develop a consequent anterior pituitary dysfunction. 
 
1.4. Methods  
I will first explore the current literature on PTPD by performing a systematic review 
on the prevalence of PTPD in patients a year or more following TBI. This systematic 
review will allow me to explore the hypothesis that PTPD affects patients with mTBI 
as well as patients with moderate and severe TBI. I then sent out a questionnaire to 
members of the Society of British Neurosurgeons (SBNS), whose membership 
includes neurosurgeons based in the UK and Ireland to determine current 
surveillance practices. 
 
The main part of the PhD involved designing a protocol for a study to determine the 
how mTBI affected pituitary function acutely and to determine the prevalence of 
PTPD 6 months following TBI. I then conducted a feasibility study using this protocol 
and focusing only on patients with mTBI. This feasibility study allowed me to 
determine the prevalence of PTPD 6 months after TBI in patients with mTBI. The 
data from patients screened and recruited for this study allowed me then to 
determine the characteristics and short-term outcomes of patients presenting to the 
emergency department with mTBI.  
 
All major components of the PhD have been published or submitted for publication. 
This is in keeping with the University of Edinburgh thesis guidelines point 1.12 “it is in 
the interest of candidates to include any relevant published papers in their thesis. 
When published paper are to be included as a thesis chapter these must include an 
introduction and conclusion and be bound into the thesis at the appropriate point. 
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Exploring the knowledge landscape: Part 1 
Paper One 
Prevalence of Anterior Pituitary Dysfunction 12 months or more following 
Traumatic Brain Injury in Adults – A systematic review and meta-analysis  
 
Introduction: In order to explore the current knowledge on pituitary dysfunction 
following TBI, I conducted a literature review. There have been reports that de novo 
anterior pituitary dysfunction can occur several months after TBI, even in patients in 
whom anterior pituitary function had previously been normal. I therefore focused on 
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Prevalence of Chronic Anterior Pituitary Dysfunction 12 months or more 
following Traumatic Brain Injury in Adults – A systematic review and meta- 
analysis  
Abstract 
The objective of this study is to systematically review clinical studies that have 
reported on the prevalence of chronic post-traumatic brain injury anterior pituitary 
dysfunction (PTPD) 12 months or more following traumatic brain injury (TBI). We 
searched Medline, Embase and Pubmed up to April 2017 and consulted 
bibliographies of narrative reviews, selected articles and conference proceedings. 
We included cohort, case-control, and cross-sectional studies enrolling at least five 
adults with primary traumatic brain injury in whom at least one anterior pituitary axis 
was assessed at least 12 months following TBI. We excluded studies in which other 
non-traumatic brain injuries were indistinguishable from TBI. Study quality was 
assessed using the Newcastle-Ottawa Scale (NOS) score. We also considered 
studies that determined growth hormone deficiency (GHD) and adrenocorticotrophic 
hormone (ACTH) reserve using provocation test to be at low risk of bias. Data were 
extracted by four independent reviewers and assessed for risk of bias using a data 
extraction form. We performed meta-analyses using random effect models and 
assessed heterogeneity using the I2 index. We identified fifty eight publications, of 
which 29 (2,756 participants) evaluating prevalence of anterior pituitary dysfunction 
at least 12 months following TBI were selected for meta-analysis. Twelve of these 
were deemed to be at low risk of bias and therefore ‘high quality’ as they had NOS 
scores greater than 8 and had used provocation tests. The overall prevalence of at 
least one anterior pituitary hormone dysfunction for all 29 studies was 32% [95% CI 
25 – 38%]. The overall prevalence in the 12 ‘high-quality’ studies was 34% [95% CI 
27 – 42%]. We observed significant heterogeneity that was not solely explained by 
the risk of bias. Studies with a higher proportion of participants with mild TBI had a 
lower prevalence of PTPD. Our results show that approximately one third of TBI 
sufferers have persistent anterior pituitary dysfunction 12 months or more following 
trauma. Future research on PTPD should differentiate between mild and 
moderate/severe TBI.   
















Traumatic Brain injury (TBI) is common, affecting between 90 and 250 people per 
100,000 Worldwide. It is the leading cause of death and disability among young 
adults1 and has significant socio-economic consequences including unemployment 
and loss of independence. Many sufferers also have long-standing physical and 
psychological symptoms that affect their rehabilitation and ability to re-engage 
socially2. These medical problems are commonly diagnosed under the umbrella term 
post-concussive syndrome (PCS) and are seldom investigated by specialists. Some 
of these patients will have ‘organic’ pathologies that remain undiagnosed3. One 
example is posttraumatic hypopituitarism (PTHP) or more accurately, posttraumatic 
pituitary dysfunction (PTPD) (as hyperprolactinaemia occurs more commonly than 
hypoprolactinaemia). PTPD was first reported over a century ago4 but in the last two 
decades, a number of studies have attempted to understand the condition better 
including its prevalence and the risk factors for developing PTPD5 6 7.  
 
A decade ago, a meta-analysis of 14 studies (1137 patients) determined the 
prevalence of chronic PTPD to be 27.5% (95% confidence interval [CI], 22.8%-
28.9%)8. This would make TBI by far the commonest cause of pituitary gland 
dysfunction. However, in this meta-analysis, there was non-selective inclusion of 
studies that had used different methods to assess pituitary function. Furthermore, 
there was no attempt to assess risk of bias of the included studies. Consequently, 
the reported prevalence of pituitary hormone deficits in the included studies varied 
considerably from negligible to nearly 50%. The lack of robust inclusion and 
exclusion criteria for the studies included in Schneider and colleagues’ meta-analysis 
has made their findings difficult to interpret and the clinical significance of PTPD still 
divides opinions. Finally, there are reports of spontaneous resolution within a year in 
some patients with PTPD whilst other authors have reported that patients sometimes 
develop spontaneous PTPD up to one year following TBI9 10 11. It follows that meta-
analyses of prevalence statistics for PTPD should take into account this propensity 






The primary aim of this meta-analysis is determine the prevalence of chronic anterior 
PTPD at least 12 months following TBI. We compared the differences in prevalence 
of anterior PTPD at 12 months or more between studies at high risk of bias and 
studies at low risk of bias. Risk of bias was determined using the Newcastle-Ottawa 
Score (NOS) and whether primary provocation testing was used for assessing GHD 
and ACTH reserve. 
 
Secondary Aim 
Our secondary aim was to determine the extent that TBI severity, determined by 
Glasgow Coma Scale (GCS) of participants, influenced the overall prevalence of 




Criteria for considering studies for this review 
This review was performed following the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) Group guidelines12. Studies were considered for inclusion if 
they were observational studies with case–control or cohort designs. Only papers 
written in English were considered for inclusion. Case series, descriptive reports and 
grey literature (unpublished abstracts) were excluded from the analysis. Participants 
in the studies were mostly adults (≥17 years old) that had sustained a TBI and were 
prospectively followed up with pituitary function blood tests. Papers reporting on 
PTPD in children were only included if the results from included children formed a 
small proportion (less than 10%) of the overall study population. The primary 
outcome measure was the prevalence (proportion) of PTPD at 12 months. 
 
Definition of PTPD, Study selection and Quality assessment 
PTPD was defined as dysfunction of at least one anterior pituitary hormone mostly 
manifesting as hormonal deficit but also as over- or under-production of prolactin at 
least 12 months following a TBI. The quality of included studies (and risk of bias) 
was assessed using a modified version of the Newcastle-Ottawa scale (NOS) 
(supplementary appendix 2)13. The NOS assesses the quality of each study using a 
star system. Studies with NOS of 8 and above were considered to be at low risk of 
bias.  Studies were considered to be at high risk of bias and therefore ‘low quality’ if 
the NOS was lower than 8. High risk of bias was indicated if there were no clear 
inclusion and exclusion criteria for participant selection, when volunteer sampling 
strategies were used, or when details surrounding clinical features and management 
of TBI relied on retrospective data or on patient recollection of events.  Studies were 
also considered to be at high risk of bias when growth hormone deficiency (GHD) 
and secondary hypoadrenalism were primarily measured using baseline tests 
instead of dynamic (provocation) tests. Acceptable provocation tests for GHD 
included glucagon stimulation test, insulin tolerance test, growth hormone release 
hormone and arginine infusion test and growth hormone releasing hexapeptide-6 
(GHRP-6) test, whereas acceptable provocation tests for secondary hypoadrenalism 
included short synacthen test (SST) or corticotrophin releasing hormone (CRH) test. 
Studies in which baseline GH or Insulin-like growth factor-1 (IGF-1) and cortisol were 
done as screening tests prior to a full provocation test were considered at high risk of 
bias.
For all other pituitary axis hormones (thyrotropin, gonadotrophin and prolactin) 
dysfunction was defined as follows: secondary hypogonadism in men was defined as 
basal free testosterone values below the normal range defined by the study group 
with or without normal or low values of gonadotrophins. In women, hypogonadism 
was defined as the development of menstrual disorders or amenorrhoea following 
TBI or as basal value of oestradiol below the cut-off defined by the study team 
(typically, this was ≤ 0·08 nmol/l). Secondary hypothyroidism was suggested by a 
free T4 value less than the cut-off defined by the authors in presence of normal or 
low TSH values. Studies were included if they reported on the prevalence of PTPD 
despite this not being the primary objective of the study but if there was enough 
information about patient selection to meet our inclusion criteria14. 
 
Search strategy for identification of studies 
Sources of published data included electronic databases Pubmed, MEDLINE and 
Embase (inception to April 2017) and written in the English language. Bibliographies 
of review articles were checked for additional studies not identified by the electronic 
search. The MEDLINE search strategy was a variation of the strategy previously 




Four authors (JE, KM, HF, JL) independently screened titles and abstracts and the 
full articles were retrieved for relevant studies and reviewed to determine their 
suitability for final inclusion. Reviewers were not blinded to the authors’ names or 
affiliated institutions. Articles were selected for inclusion based on the pre-defined 
selection criteria. The output of all searches was exported into Microsoft Excel and 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRIMSA)16 statement was followed at all three stages (figure 1). Disagreements 
were resolved by consensus. 
 
When an article reported on several types of brain injuries only TBI data were used. 
We  omitted articles in which TBI data were indistinguishable from other types of 
brain injury such as blast injuries17 18, subarachnoid haemorrhage19 or chronic 
subdural haematoma20 and data related to repetitive brain injuries for example in 
relation to long-term involvement in contact sports21 22.  
 
Data extraction and statistical analysis 
Data including patient demographics, injury severity, cause of TBI and 
prevalence/proportion of PTPD in the cohort were extracted using a data extraction 
form. R Studio, version 3.4.1, was used for statistical analysis. A random effects 
model in the metafor package was used to calculate pooled prevalence estimates 
with 95% CIs. Heterogeneity was assessed using the I2 measure with significance 
set at p < 0.05.  
 
Patient involvement 
There were no patients involved at any stages of setting up or executing this 
research. There was also no patient involvement in the analysis of results and writing 
up the final manuscript. The results of this study have not been made available to 
any patient groups. 
 
Results 
Our initial search identified 1655 publications. A flow diagram of the selection 
process is presented in Fig. 1. A total of 418 duplicate publications were removed, 
and of the remaining 1237 original articles, 1160 were excluded as irrelevant to the 
study objectives based on their titles and abstracts. A total of 58 full-text articles 
were reviewed and 29 articles that did not meet the selection criteria were excluded23 
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 (table 1). Ultimately, 29 
studies met the inclusion criteria. Twelve studies were deemed to be at low risk of 
bias with NOS ≥ 8 and provocation testing used for GHD and ACTH reserve52 53 54 55 
56 57 58 59 60 61 62 63. The median age of patients in the 29 studies was 37.45 years and 
the median time to testing following TBI was 19.5 months (table 2). The median GCS 
of participants at the time of injury was 8 (range 4 to 12). Information about the 
cause of TBI was available for two-thirds of participants and the commonest causes 
of TBI were road traffic accidents (53%), falls (28%) and assault 6%). There were 17 
studies determined to be at high risk of bias (table 2).  
 
Primary aim - Prevalence of anterior PTPD at 12 months or more after TBI 
The 29 included studies had 2756 participants (67% males). The overall prevalence 
of any chronic anterior PTPD (more than one hormone deficiency) was 31.86% [95% 
CI 25.25– 38.46%] (Figure 2). Using a fixed effects model the I2 was 95.89%. The 
prevalence of individual hormone deficiencies for all 29 studies at 12 months are 
shown in table 2. The mean ages of the cohorts in the twelve studies (1112 
participants) deemed to be at low risk of bias ranged from 31 – 53 (median 35.76) 
and the median time from TBI to testing for pituitary function was 18 months. Growth 
hormone deficiency was the most common individual hormone deficiency at 12 or 
more months following TBI with a mean of 22% (range 2.7% to 63.6%) and hypo- 
and hyperprolactinaemia were the least common with averages of  3.6% (range 0 to 
14.3%) and 4.8% (range 0 – 11.8%), respectively. Hypogonadism was the second 
most common deficiency (average 10.2%; range 0-28%), followed by secondary 
hypoadrenalism (10%; range 0 – 43%) and hypothyroidism (6.2%; range 0-22%). 
 
To determine the influence of study quality on prevalence of PTPD, we compared 
the overall prevalence of studies at high risk of bias with the overall prevalence of 
studies at low risk of bias. The combined prevalence of PTPD at 12 months or more 
following TBI in the  12 studies deemed at low risk of bias (1112 participants) was 
34.05.% [95% CI 26.5. – 41.6%]. The rate of PTPD varied considerably from 5.4% to 
75%. There was also significant statistical heterogeneity: using a fixed effects model 
the I2 was 86.5% (see figure 2). TBI severity was reported in 11 of the 12 studies and 
of these, only 16.4% of the included participants had a mild TBI (total of 920 
participants; 67% male). The median GCS at the time of injury for participants in 
these 12 studies was 8. The commonest reported causes of TBI were road traffic 
accidents (54%) and falls (23%). The most common hormone deficiency in these 14 
studies was GH deficiency (22.8%), followed by secondary hypoadrenalism (12%) 
and secondary hypogonadism (8.6%). Secondary hypothyroidism was uncommon as 
were hyper- and hypo-prolactinaemia. Individual hormone deficiencies with 
confidence intervals are listed in table 3. Seventeen studies (1644 participants; 
67.6% male) were deemed to be at high risk of bias either because they had not 
used provocation tests to determine GHD or ACTH reserve or because they had an 
NOS score below 8 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80. We divided these 17 studies 
into 2 groups for comparison: those determined to be at high risk of bias based on 
NOS < 8 (5 in total) and those that did not use provocation tests for GHD and 
secondary hypoadrenalism (9 in total). Three studies had both an NOS < 8 and had 
not used provocation testing in their primary assessment of pituitary function64 65 80. 
The overall prevalence of PTPD in these 17 studies was 30.3% [95% CI 20.3-
40.3%). Using a fixed effects model the I2 was 97.54%. There was no statistical 
difference between the overall prevalence of the ‘high’ and low quality studies 
(p=0.77). Studies with NOS scores of 7 had a lower overall prevalence of PTPD at 
12 or more months compared to studies with NOS of 8 (24% vs. 35%) but this 
difference did not reach statistical significance (p = 0.12). There was also no 
statistically significant difference between the overall prevalence of PTPD reported 
for studies that used primary provocation tests versus studies that did not (p=0.72). 
Finally, we calculated the overall prevalence of more than one hormone dysfunction 
at 12 or more months following TBI for all 29 studies. This overall prevalence 
dropped significantly to 6.7% [CI 0.45 to 8.8%] (figure 3). 
 
Secondary aim - Influence of injury severity 
To determine whether injury severity as determined by GCS influenced the reported 
prevalence of chronic anterior PTPD at 12 months, we divided all 29 studies into 
studies in which at least 50% of participants had suffered a mild TBI (GCS 13-15) 
and studies in which less than 50% of participants had suffered a mild TBI. Nineteen 
of the 29 studies35 36 37 38 39 40 41 42 43 44 45 46 48 49 had less than 50% of participants with 
mild TBI (greater proportion with moderate and severe TBI) and 5 had more than 
50% participants with mild head injury (lower proportions with moderate and severe 
TBI)28 46 47. Five studies did not report the injury severity of participants. The overall 
prevalence of PTPD was higher for studies in which less than 50% of included 
participants suffered mild TBI (31.7%; 95% CI 24.8 – 38.7%) compared to the group 
in which more than 50% of participants suffered mild TBI (20.6% ;95% CI 3.5%-
37.6%). However, this difference did not reach statistical significance (p=0.44)(figure 
4). 
Discussions 
In our meta-analysis we compared the overall prevalence for PTPD 12 months 
following TBI reported for studies at low risk and studies at high risk of bias. We 
found a similar overall prevalence in both groups. The overall prevalence of deficit of 
at least one anterior pituitary hormone in both groups were 29% and 31.2% 
respectively, suggesting that a significant number of TBI sufferers are at risk of 
developing anterior PTPD at least one year following TBI. This prevalence rate is 
comparable to previous meta-analyses by Schneider and colleagues and more 
recently Lauzier and colleagues815. Schneider and colleagues were criticised for not 
differentiating between studies at high and low risks of bias, particularly the different 
methods that were used to test GHD and secondary hypoadrenalism. Our results 
however suggest that this did not make a difference to the overall prevalence of 
approximately one-third. The prevalence of PTPD was however influenced by injury 
severity and the greater the number of patients with mild TBIs in a cohort, the lower 
the prevalence of PTPD. 
 
Although the clinical significance of chronic anterior PTPD remains controversial, 
untreated hypopituitarism may contribute to the neurobehavioral problems suffered 
by many TBI patients, which may ultimately affect rehabilitation in TBI sufferers. 
Hormone-replacement therapy in these patients may improve these symptoms. 
Although several groups have provided guidelines for screening81, there is little 
evidence that surveillance is widespread. As with previous meta-analyses, the 
limitations were the heterogeneity of studies on PTPD as well as the relatively small 
number of participants in the existing studies. This meant that despite our attempts 
to reduce bias by stratifying study quality using the NOS score, there remained 
significant bias in the studies used for the meta-analysis. We used the random-
effects model in our analyses to allow for the heterogeneity of variance between 
studies. The I2 for the studies with high NOS and that used provocation test was 
94% and I2 for studies the others was 90%. This makes it difficult to formulate a 
unified ‘one-size-fits-all’ surveillance guidance. A prospective, large study is required 
to develop surveillance guidelines in the future. 
 
Our secondary objective was to determine whether injury severity affected 
prevalence of chronic anterior PTPD. We dichotomised all studies reporting on 
prevalence of PTPD at 12 months into studies in which greater than 50% of included 
participants had a mild TBI (GCS 13 – 15) and studies in which the proportion of 
participants with mild TBI was less than 50%. The overall prevalence of chronic 
anterior PTPD was  higher in the group with less patients with mild TBI but this 
difference did not reach statistical significance (32% vs. 21%, pp=0.44). This 
suggests that injury severity may have a greater influence on the occurrence of 
chronic PTPD than the pituitary function test methodology or study quality. This is an 
important point because it suggests single baseline assessments of pituitary function 
may be as good an assessment as of pituitary function in this cohort as provocation 
studies which are difficult to implement in research participants because they are 
time consuming. 
 
The association between PTPD and TBI severity has previously been suggested. 
Schneider et al demonstrated an association between injury severity and higher 
prevalence of chronic PTPD. In their meta-analysis, 35.5% of participants who had 
suffered a severe TBI (GCS ≤ 8) developed chronic PTPD compared to 16.8% of 
participants that had suffered a mild TBI. Interestingly the prevalence of PTPD in 
participants that had suffered a moderate TBI (GCS 9-12) was 10.9%8. Likewise, 
Lauzier and colleagues reported an association between increased injury severity 
and increased risk of anterior pituitary disorders with a risk ratio of 1.91 [95% CI, 
1.17-3.13] for patients with non-mild vs. mild TBI. The influence of injury severity is 
corroborated by our results. However, there was insufficient data to explore the 
extent of this influence further. Future studies will need to differentiate between mild 
and non-mild TBI to reduce the study bias. Alternatively, an individual patient meta-
analysis could be performed to better establish the relationship between injury 
severity and PTPD. 
 
The strength of this meta-analysis is that it is the first meta-analysis on chronic 
anterior PTPD that takes into account the quality of the studies reporting on PTPD 
and the differences in the methodologies used by each study. We used a 
comprehensive search strategy, included new studies and have increased the body 
of literature summarised since the last review15. Despite these efforts, we have found 
significant inter-study heterogeneity. A large, multi-centre, prospective study is 
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Figure 1. Study selection process 
N=1655 records identified 
through database search 
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Figure 2. Overall prevalence rate with 95% confidence intervals of at least one pituitary hormone dysfunction 12 months or more following TBI for the 29 
studies included in meta-analysis 
 
Figure 3. Overall Prevalence with 95% confidence intervals of more than one anterior pituitary hormone dysfunction 12 or more months following TBI 
   
Figure 4. Influence of injury severity on prevalence of PTPD. Studies with more participants with mild TBI had a lower prevalence of PTPD.
Authors Reason for not using 
Abadi et al23  Less than one year follow up 
Agha et al24 Less than one year follow up 
Aimeretti et al25 Less than one year follow up 
Alavi et al26 Less than one year follow up 
Bavisetty et al27 Less than one year follow up 
Baxter et al28 Less than one year follow up 
Bondanelli et al29 Replicated data 
Bushnik et al30 Retrospective data 
Englander et al31 Retrospective data 
Guilano et al32 Retrospective data 
Hannon et al33 Less than one year follow up 
Ioachimescu et al34 Retrospective data 
Izzo et al35 Retrospective data 
Kelly et al36 Less than one year follow up 
Kelly et al37 Less than one year follow up 
Kopczak et al38 
TBI data indistinguishable from other forms 
of HI 
Kreber et al39 Retrospective data 
Krewer et al40 
TBI data indistinguishable from other forms 
of HI 
Leal-Cerro et al41 Retrospective data 
Leon-Carron et al42 Less than one year follow up 
Lieberman et al43 Retrospective data 
Marina et al et al44 Replicated data 
Mossberg et al45 Less than one year follow up 
Pavlovic et al46 Retrospective data 
Srinivasan et al47 Retrospective data 
Tandon et al48 Less than one year follow up 
Tanriverdi et al49 Replicated data 
Tanriverdi et al50 Replicated data 
Wilkinson et al51 
TBI data indistinguishable from other forms 
of HI 
Table 1. Studies excluded from meta-analysis 
 
Authors Year Sample size NOS Dynamic test 
Studies at low risk of bias 
Agha et al52 2004 102 8 Yes 
Cuesta et al53 2016 112 8 Yes 
High et al54 2010 83 8 Yes 
Jeong et al55 2010 65 8 Yes 
Kleindienst et al56 2009 71 8 Yes 
Klose et al*57 2007 104 8 Yes 
Klose et al**58 2007 46 8 Yes 
Nourollahi et al59 2014 97 8 Yes 
Schneider et al60 2006 78 8 Yes 
Silva et al61 2015 165 8 Yes 
Ulfarsson et al62 2010 51 8 Yes 
Zgarljardic et al63 2011 138 8 Yes 
Studies at high risk of bias 
Aimeretti et al64 2005 23 7 No 
Aimeretti et al65 2005 70 7 No 
Berg et al66 2010 246 8 Mixed 
Bodanelli et al67 2004 50 8 Mixed 
Hermann et al68 2006 76 8 Mixed 
Kozlowski Moreau et al69 2012 55 8 Mixed 
Kumar et al70 2016 56 8 Mixed 
Nemes et al71 2016 63 8 Mixed 
Popovic et al72 2004 67 8 Mixed 
Prodam et al73 2013 54 8 Mixed 
Wachter et al74 2009 9 8 Mixed 
Klose et al***75 2014 426 7 Mixed 
Kokshoorn et al76 2011 112 7 Mixed 
Krahulik et al77 2010 89 7 Mixed 
Park et al78 2010 45 7 Mixed 
Tanriverdi et al79 2011 52 7 Mixed 
Van der Eerden et al80 2010 107 7 No 
Table 2. Studies included in meta-analysis 
 
 
Hormone dysfunction Overall prevalence (%) [95% CI] 
Growth hormone deficiency 19.1% [11.5 – 26.6] 
Secondary Hypoadrenalism 8.9% [4.1 – 13.8] 
Secondary Hypogonadism 6.2% [2.9 – 9.4] 
Secondary Hypothyroidism 1.2% [0.4 – 1.9] 
Hyperprolactinaemia 1.7% [0.6 – 2.8] 
Hypoprolactinaemia 1.2% [ 0.4 – 1.9] 
Table 3. Overall prevalence rates with 95% confidence intervals of individual hormone dysfunction 
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Medline search strategy 
1. head trauma OR head injury OR head injuries OR brain trauma OR brain injury 
OR brain injuries OR cerebral trauma OR cerebral injury OR cerebral injuries OR 
craniocerebral trauma OR craniocerebral injury OR craniocerebral injuries OR tbi OR 
traumatic brain injury OR traumatic brain injuries OR brainstem trauma OR 
brainstem injury OR brainstem injuries OR Craniocerebral Trauma OR brain edema 
OR brain hernia OR intracranial hypertension OR Brain Edema OR Intracranial 
Hypertension  
2. pituitary gland OR hypophysis OR hypophysis function OR pituitary hormone OR 
adenohypophysis hormone* OR neurohypophysis hormone* OR pituitary hormone-
releasing hormone* OR pituitary function test* OR pituitary disease OR hypophysis 
disease OR neuroendocrine disease OR hypothalamus hypophysis system OR 
hypothalamus OR hypothalamus function OR hypothalamus hormone* OR 
hypothalamus lesion* OR hypothalamus disease OR pituitary-adrenal system OR 
hypothalamus hypophysis adrenal system OR hypophysis adrenal system OR 
adrenal cortex hormone* OR  adrenocorticotropic hormone* OR hydrocortisone OR 
corticotropin release OR corticotrophin release OR corticotropin blood level OR 
corticotrophin blood level OR corticosteroid blood level OR pituitary-adrenal function 
test* OR corticotropin test* OR adrenal insufficiency OR corticosteroid therapy OR 





congeners OR estradiol OR estradiol congeners OR testosterone OR testosterone 
congener* OR androgen* OR androgen blood level OR estrogen* OR estrogen blood 
level OR progestin* OR androstenol* OR follitropin release OR follitrophin release 
OR follitropin blood level OR follitrophin blood level OR gonadotropin release OR 
gonadotrophin release OR gonadotropin blood level OR gonadotrophin blood level 
OR gestagen blood level OR luteinizing hormone blood level OR luteinizing hormone 
release OR hypogonadism OR hypogonadotropic hypogonadism OR ovary 
insufficiency OR estrogen deficiency OR androgen deficiency OR estrogen therapy 
OR androgen therapy OR hypothalamus hypophysis thyroid system OR thyroid 
hormone* OR thyroid hormone blood level OR thyrotropin release OR thyrotrophin 
release OR thyrotropin blood level OR thyrotrophin blood level OR thyroid function 
test* OR euthyroid sick syndrome* OR hypothyroidism OR diabetes insipidus OR 
vasopressin release OR vasopressin blood level OR insuline-like growth factor* OR 
growth hormone release OR growth hormone blood level OR somatomedin C OR 
growth hormone deficiency OR prolactin synthesis OR prolactin release OR prolactin 
blood level or hyperprolactinemia OR Pituitary Diseases OR Pituitary Hormones OR 
Pituitary Hormone-Releasing Hormones OR Diagnostic Techniques, Endocrine OR 
Hypothalamus OR Pituitary-Adrenal System OR Adrenal Insufficiency OR Adrenal 
Cortex Hormones OR Gonadal Steroid Hormones OR Androgens OR Estrogens OR 
Progestins OR Androstenols OR Hypogonadism OR Euthyroid Sick Syndromes OR 
Hypothyroidism OR Thyroid Hormones OR Insulin-Like Growth Factor 1 
 








The systematic review confirms that PTPD is a common and significant clinical entity 
and that full assessment of pituitary function should be considered in the chronic 
phase of recovery from TBI to detect anterior pituitary deficiency, which is reversible 






















Exploring the research background: Part 2 
Paper 2: A national survey of clinical practice of surveillance for post-traumatic brain 
injury hypopituitarism in the United Kingdom and Ireland 
 
Introduction:  
Having established in my systematic review that one-third of patients with TBI 
followed up with pituitary testing had evidence of anterior pituitary dysfunction, I 
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Background: Traumatic brain injury (TBI) is the most common cause of death and 
disability in young adults in industrialised countries. Post-TBI hypopituitarism (PTHP) 
is thought to occur in one-third of patients, however the natural history and predictive 
factors are not fully understood and as such guidelines for surveillance vary. The aim 
of this study was to assess the variations in current surveillance practices across the 
Neurosurgery Centres within the United Kingdom. 
 
Methods: A questionnaire was developed following discussions with an expert panel 
and distributed to members of the Society of British Neurosurgeons (SBNS), by 
email and printed copy, to survey surveillance practices for PTHP. The questionnaire 
primarily aimed to determine how commonly screening was performed and the 
clinical parameters used to guide these surveillance practices. 
 
Results: There were 45 responders representing Neurosurgery units in regions of 
England, Scotland and Ireland. The majority of participants (86.7%) considered 
PTHP to be a problem but only 25% (11/45) routinely screened for PTHP. There was 
wide variation in the criteria used to determine which patients were screened. 
 
Conclusions: Our survey suggests that few Neurosurgeons routinely screen for 
PTHP and those that do use a wide variation of clinical parameters to guide 
surveillance practice. A UK-wide prospective cohort study may help identify patients 








Traumatic brain injury (TBI) is a significant public health problem worldwide, with an 
overall incidence in Western countries of 200–235 cases per 100,000 individuals 
annually1. It is the leading cause of death and disabilities worldwide amongst young 
people under 40 years old. There are also significant health and socioeconomic 
consequences, with many sufferers developing chronic physical and mental health 
problems that prevent them from working or re-engaging socially after their injuries. 
There have been many advances made in supportive rehabilitation but very few 
therapeutic interventions that effect outcomes in patients recovering from TBI. One 
potential therapeutic avenue is diagnosis and treatment of post-TBI hypopituitarism 
(PTHP). 
PTHP was first described over a century ago2 and in the last 2 decades there has 
been a renewed interest in its clinical implications with two meta-analyses concluding 
that PTHP occurs in approximately one-third of TBI patients that are followed up long 
term3,4.The risk factors for developing PTHP are less clear and this has made 
guidelines for surveillance difficult to establish. Our aim in this study was to survey 
the surveillance practices of Neurosurgeons in the United Kingdom (UK) and Ireland. 
 
Method 
An online questionnaire survey was designed using Google Survey and the contents 
of the questionnaire were informed by discussions with an expert panel that included 
a consultant neuro-intensivist, a consultant endocrinologist and a consultant 
neurosurgeon. After approval by the academic committee of the Society of British 





including consultants and trainees. To encourage members’ participation, they were 
offered the possibility to be entered into a draw for a £50 gift voucher. The survey 
was open between 13th April 2017 and 19th June 2017 and an email reminder was 
sent after one month. There were a total of 11 questions designed to determine the 
region of the UK in which the responder worked and the surveillance practice of the 
responder. Nine questions focused on surveillance practice (see Table 1). 
Results 
Forty-five UK and Irish Neurosurgeons from 25 neurosurgery centres completed the 
questionnaire with broad regional representation (Table 2). Two-thirds of responders 
were consultant Neurosurgeons. There are approximately 600 SBNS members. 
When asked whether participants considered PTHP a clinical problem, the majority 
of responding Neurosurgeons (86.7%) answered ‘yes’ (8.9% considered PTHP a 
major clinical problem, 37.8% considered it a moderate clinical problem and 40% 
considered it a minor problem), while only 6.7% did not consider PTHP to be a 
clinical problem. A small number (6.7%) answered ‘I don’t know’ (Figure 1(a)). 
Furthermore, just over half (56.6%) of responders thought that evidence of pituitary 
dysfunction should be routinely assessed in patients that suffer TBI (Figure 1(b)). 
13% of those who thought that evidence of pituitary dysfunction should be routinely 
checked provided clinical scenarios that should prompt pituitary screening. These 
included: “if there is [evidence of] sphenoidal basal fractures”, “if able to” and “only 
for moderate and severe TBIs”. Despite these responses, the majority of 
Neurosurgeons (76.1%) did not routinely check pituitary function in patients 






What clinical parameters prompt screening? 
All participants answered the question “how do you decide which patients to 
screen?” Of these, 50% answered “I don’t routinely screen”, 34.8% answered “I only 
screen if there are clinical features suggestive of PTHP” and 15.2% answered “I 
screen based on clinical severity”. None of the participants screened based on 
duration of stay in hospital (Table 1). Most of the participants that checked pituitary 
function based on injury severity used more than one clinical markers of injury 
severity. The most commonly used severity parameter was admission Glasgow 
Coma Scale (GCS) (80%) and the neuro-imaging findings (46.7%). Duration of loss 
of consciousness and duration of post-traumatic amnesia were less commonly used 
(see Table 1). 
 
Timing of screening 
The most common timing for screening was between one and six months following 
TBI (28%). Only 16% and 8% of participants that routinely screened did so within 
one month and within one week of TBI, respectively. Nearly One-quarter (24%) of 
the participants did not have a specific interval during which they routinely screened 
patients. 
 
What screening tests are performed? 
When a surveillance pituitary function test was performed, the most commonly tested 
pathways were the pituitary-adrenal axis (92%), the pituitary-thyroid axis (76%) and 





of participants that routinely screened, respectively and the pituitary-somatotropic 
axis or pituitary-growth axis was tested by 32%. Only 5 participants responded to the 
question about what GH axis test they performed: 3 stated that they checked Insulin-
like Growth Factor-1 (IGF-1), one stated that they did a GH stimulation test (but did 
not specify which) and the 5th responder did not know what tests were routinely 
done for GH axis. 
 
Discussion 
Although subjective and with only a relatively small number of participants, our 
survey highlights the variations in the perceived clinical importance of PTHP and the 
surveillance practices amongst Neurosurgeons in the UK and Ireland. We found that 
while the majority of Neurosurgeons agreeing that PTHP is an important clinical 
problem, only approximately one-quarter routinely screen patients and of those that 
do, the clinical parameters that prompt screening and the post-injury interval to 
screening also varies considerably. These variations in clinical practice are likely due 
to the lack of widely accepted guidelines. Over the years, there have been several 
attempts to influence surveillance practice5 including the recent guidelines issued by 
the British Neurotrauma Group6. However, the influences of such guidelines remain 
uncertain because none have been able to identify any definitive clinical or 
radiological risk factors attributed to the development of PTHP and as such it is 
difficult to know which patients to screen. The high incidence of TBI globally and in 






One difficulty with research into the prevalence and risk factors for PTHP is that 
there are disparities in the methodologies used by different researchers to diagnose 
PTHP. For example, some researchers have tested for secondary hypoadrenalism 
and growth hormone deficiency (GHD) with stimulation blood tests whilst others have 
used baseline blood tests only. There have also been differences in the intervals to 
surveillance, ranging from 3 months to 12 months. This has meant a wide variation in 
the reported prevalence of PTHP. Two meta-analyses have concluded the overall 
prevalence of PTHP to be 27.5% and 30%. However, reports of an association 
between PTHP and higher severity TBIs7,8 or with certain imaging characteristics 
such as in patients with base of skull fractures9. 
In the recently published British Neurotrauma Group guidelines, screening for PTHP 
was recommended at 3 to 6 months for patients admitted for 48 hours or more 
following TBI or those who have symptoms suggestive of ‘pituitary dysfunction’ or in 
patients who are symptomatic 12 months or more following TBI. This 
recommendation is congruous with the reports that in serially followed up patients, 
PTHP appears to be a dynamic problem during which early pituitary dysfunction may 
resolve, whilst in other patients, pituitary dysfunction may present late and as such 
late development of PTHP (6 months or more after TBI) may be missed. However, 
one potential difficulty with the screening recommendations of the British 
Neurotrauma Group guidelines, which the group highlighted, is that many of the 
symptoms of hypopituitarism overlap with the cluster of symptoms that can occur 
after TBI and which are commonly referred to under the umbrella term post-
concussion syndrome (PCS). Screening based on patients’ symptoms may therefore 
lead to over-screening in patients with persistent PCS symptoms. A prospective 





problem. Nonetheless, the British Neurotrauma group guidelines are a 
comprehensive set of guidelines for PTHP surveillance for UK based 
neurosurgerons 
Finally, it should be noted that because the majority of studies on PTHP have 
recruited patients with moderate and severe TBIs, guidelines based on such studies 
cannot be extrapolated to patients that suffer mild TBI. As the majority of TBI 
sufferers are those that sustain a ‘mild’ TBI, such guidelines therefore have limited 
scope in influencing surveillance practices for patients with mild TBI. A large, 
prospective study is needed to determine the prevalence of PTHP in patients with all 
types of TBI including mild TBI, and to help formulate appropriate guidelines for 
these patients. 
The main limitation of our study is that there were only a small number of responders 
and therefore the results are not reflective of the practices of all Neurosurgeons in 
the UK and Ireland. Additionally, most of the responders were neurosurgeons 
practicing in Scotland (where the authors also practice) and as such our findings 
could be skewed towards Scottish practice rather than the UK as a whole.. The 
overall picture is further affected by our questionnaire design which allowed 
participants who do not routinely screen patients to answer subsequent questions 
about how patients are screened. Furthermore, patients with acute neurotrauma are 
not always directly managed by neurosurgeons in some hospitals and likewise, 
neurosurgeons may not be involved in the long-term management of this patient 
group. This indicates that the overview of practice we have highlighted in this study 
may not be an accurate reflection of the clinical practices across all specialists 





amongst other clinicians such as rehabilitation physicians, in order to get a better 
idea of surveillance practices. 
Conclusion 
In summary, our study shows that despite guidelines, the surveillance practices for 
PTHP vary considerably in the UK and Ireland amongst neurosurgeons. These 
variations are in part due to the ongoing debate about the clinical significance of 
PTHP. Given the health and socioeconomic burden of TBI, a UK-wide study is 
needed to define the prevalence of PTHP, its risk factors and to help formulate 
evidence-based recommendations for surveillance practices. 
Table 1. The nine questions about surveillance practices and corresponding 
responses. 
Questions about surveillance practices for PTHP Responses (proportion of responders) 
Do you consider PTHP a problem? No (6.7%) 
Yes, minor (40%) 
Yes, moderate (37.8%) 
Yes, Major (8.9%) 
I don’t know (6.7%) 




I don’t know (26%) 




4. If your answer [to question 3] is yes, how do you 
decide which patients to check? 
I don’t routinely screen patients (50%) 
I screen patients that are in hospital for 
longer than a certain period 





Questions about surveillance practices for PTHP Responses (proportion of responders) 
(34.8%) 
I only screen if there are clinical features 
suggestive of PTHP (15.2%) 
5. If you screen based on duration of hospital stay, please 
state threshold duration 
0% 
6. If you screen based on injury severity, which criteria do 
you use? 
Admission GCS (80%) 
Imaging (46.7%) 
Duration of loss of consciousness (20%) 
Duration of posttraumatic amnesia 
(33.3%) 
7. If your answer [to question 3] is yes, when do you 
screen? (you may select more than one answer) 
Within 1 week of TBI (8%) 
Within 1 month of TBI (16%) 
Between 1 and 6 months of TBI (28%) 
After 6 months (4%) 
Only if clinically indicated (28%) 
No specific routine (24%) 
8. If your answer [to question 3] is yes, what tests do you 
perform? (you may select more than one) 
Growth-hormone (GH) function (32%) 
Pituitary-adrenal pathway/axis (92%) 
Pituitary-thyroid pathway/axis (76%) 
Female sex hormone pathways/axes 
(32%) 
Male sex hormone pathways/axes (36%) 
Prolactin (40%) 
9. Please state which test(s) you do for GH axis IGF-1 (6.6%) 
GH stimulation test (2.2%) 








Table 2. Regions of the UK and Ireland represented by the 45 responders. 




Northwest England 5 
Northeast England 5 
Yorkshire 2 
West Midlands 4 
East Midlands 2 
East of England 1 
Southeast England 4 
Southwest England 1 
South of England 1 
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The prevalence of post-traumatic brain injury pituitary dysfunction (PTPD) has been 
difficult to determine as has the pathogenesis. There is a need for better 
understanding of PTPD as it offers a potentially treatable cause of morbidity in 
traumatic brain injury (TBI) sufferers. 
Methods 
A pilot observational study was conducted to test the feasibility of a prospective 
study to determine how hormonal and structural responses of the anterior pituitary 
gland to TBI. Adults (> 17 years of age) who had recently suffered a TBI were eligible 
for inclusion if they did not have a prior endocrine disease or did not take any 
medications that affected the hypothalamo-pituitary axes. Participants were followed 
up with baseline anterior pituitary and magnetic resonance imaging (MRI) of their 
pituitary gland within a week of injury and further MRI and anterior pituitary function 
tests including stimulation tests for growth hormone and adrenocorticotropic 
hormone function six months after injury. Primary outcomes were the feasibility of 
participant recruitment, participant retention and assessment procedures. 
Results 
Between August 2017 and July 2018 (11 months), 926 patients were screened and 
54 (5.8%) were recruited. Only 36 of the 54 recruited patients (66.7%) returned for 
the first visit. The median age of the returning patients was 38.5 years (IQR27.5-59.5 
years) and there was an even distribution of female (58%) and male (42%) returners. 
Only 15 of the 36 patients who attended the first study visit returned for the second 





study to a two visit study. All participants who were tested tolerated blood tests 




We adapted the protocol to reduce burden on participants. The results suggests that 
the trial methodology of the modified protocol are feasible for implementing an 







• What uncertainties existed regarding the feasibility? 
Prior to this pilot study, it was unknown whether it is possible to perform a 
prospective study to determine the prevalence and risks of developing 
anterior pituitary gland dysfunction after TBI. 
• What are the key feasibility findings? 
Our results suggest that the trial methodology and interventions in the 
PitSTOP study protocol are feasible for implementing such a study in patients 
with mild TBI. We found a high attrition rate in this cohort and therefore 
adapted the protocol by reducing the number of visits to reduce the study 
burden on participants. 






The high attrition rate and low screened-to-recruitment ratio indicated that a 





















































Traumatic brain injury (TBI) is the “silent epidemic” of the 20th century. It is a major 
health problem worldwide [1]. Up to 250 people per 100,000 per year die or are 
hospitalised because of TBI and many more patients are discharged from 
emergency departments without input from specialists. Furthermore, TBIs 
disproportionately affect young people and is the leading cause of death and 
disability in patients under 40 years old in the United Kingdom, meaning that there 
are also significant socioeconomic consequences. In the United States, the direct 
and indirect costs of TBI are estimated at $ 56 billion [2]. In less developed countries, 
the incidence of TBI is higher and rapidly increasing [3]. In Scotland, the rate of 
continuous hospital stays as a result of TBI has been calculated as 446 per 100000 
for men and 195 per 100000 for women [4]. This is higher than elsewhere in Europe 
and represents a significant and unique health challenge to the National Health 
Service in Scotland.  
 
The majority of TBI patients are managed in and discharged from non-specialist 
centres with little or no scope for follow-up and as a result there are many patients 
with undiagnosed medical problems related to TBI that develop over days, weeks 
and months following TBI. One such chronic problem is TBI-related pituitary 
hormone dysfunction (post-TBI pituitary dysfunction or PTPD). It may affect as many 
as 25% of patients after TBI. The pituitary gland sits at the centre of the brain and is 
a major endocrine organ that regulates key homeostatic functions (the body’s 
balancing system) from basal metabolic rate to mental wellbeing and sexual function. 
Many of the symptoms of PTPD, especially the psychological disturbances such as 





symptoms of post-concussion syndrome, which has become an umbrella term for 
many of these problems. Furthermore, the symptoms may develop several months 
after TBI, which further compounds diagnoses. Symptoms of PTPD are reversible 
with effective treatment and it is therefore important that affected patients are 
identified and treated appropriately. There has been very little progress made on 
post-event therapies in TBIs over the past two decades. Developing an effective 
screening tool for PTPD offers the opportunity to improve diagnoses, offer early 
treatments and improve the rehabilitation and recovery of many TBI patients. 
 
The primary outcomes of this pilot study were to test the feasibility of the PitSTOP 
Study protocol and to inform a sample size calculation for the main study using the 
pilot phase data. The main questions  
• Is it possible to consent patients after mild traumatic brain injury? 
• What is the screened to consented ratio? 
• Will consented patients return for subsequent visits including for 
stimulation tests of their anterior pituitary function which requires 
fasting from midnight and an MRI scan of brain? 
• Can pituitary anatomy including vascular anatomy be assessed using 
our bespoke MRI image sequences? 
 
4.3. Methods 
Design and recruitment 
This was a longitudinal, prospective observational study. Participants were recruited 
from the emergency department of the Royal Infirmary of Edinburgh over a 12-month 
period (figure 1). Patients who present to the emergency department with a history of 





The inclusion criteria were: 
1) Primary traumatic Brain Injury (TBI) including multi trauma with a post 
resuscitation Glasgow Coma Scale score or 13 to 15 (mild TBI) 
2) patients aged ≥ 17 years at the time of TBI 
3) Informed consent obtained from participant  
The exclusion criteria were: 
1) Patients with a pre-existing endocrine diagnosis 
2) Morbidly obese patients with BMI > 35 
3) Unlikely to survive for the next 24 hours in the opinion of the Intensive care or 
Neurosurgical team treating the patient 
4) Patients with known epilepsy 
5) Patients on medications that are known to affect the hypothalamic-pituitary 
axis 
6) Patients who are not able to consent 
 
Research Ethics 
This study was approved by the Lothian Ethics of Medical Research Committee 
(Reference number: 17/SS/0043). All participants provided written informed consent 
prior to participation in this research. 
Participant characteristics 
Information on patient demographics age, gender, ethnicity, mechanism of injury, 







Data sources and measurements 
Once recruited, the participants were initially to be followed up for up to 12 months 
with three planned visits (Figure 1).  However, poor participant retention necessitated 
protocol modification with revised protocol requiring 2 visits over 6 months. There 
were therefore 2 stages: 
1.  Recruitment and baseline assessments (Day 0 to 7 after the TBI) 
Participants had fasting early morning (between 8am and 10am) blood tests for 
anterior pituitary hormones levels within 7 days of TBI. These included serum levels 
of cortisol, insulin-like growth factor 1 (IGF-1), testosterone, thyroxine (fT4), thyroid 
stimulating hormone (TSH), oestradiol. Some participants had an MRI scan of their 
pituitary gland with the following sequences being performed. 
- sagittal 3D T2-weighted 
- sagittal 3D SPGR/MPRAGE T1-weighted 
- sagittal 3D T2 Fluid-Attenuated Inversion Recovery (FLAIR) 
- gradient echo and / or axial 3D Susceptibility Weighted Imaging (SWI) 
 
2. Follow-up visit 1 (6months +/- One month after TBI) 
Fasting, early morning anterior pituitary hormone profile was repeated including 
stimulation tests to access growth hormone (GH) and adrenocorticotropic hormone 
(ACTH) function [5]. Participants who had an MRI scan during the recruitment visit 
had the same sequences repeated. Participants were asked at this stage to 
complete an extended Glasgow Outcome Score (GOSE) questionnaire [6]. 
 









Our targeted sample size was 100 participants. As this was a pilot study, a formal 
sample size calculation was not conducted. A sample of 100 participants was 
chosen because it was felt this would be a large enough sample to allow an accurate 
assessment of the feasibility of recruitment, retention, outcome measure completion, 
and testing the capacity for accommodating research blood tests and neuroimaging.  
 
Feasibility Outcomes 
1. Primary outcomes: Recruitment and retention 
The primary outcomes were to assess the recruitment and retention rates. 
Recruitment was defined as the number of new patients that consented to 
take part in the study and retention was the proportion of recruited patients 
who completed the subsequent visits. 
2. Secondary Outcomes: Assessing assessments  
The secondary was to assess whether the blood sampling and stimulation 
tests could be achieved without adverse effects and whether our bespoke 
MRI sequences could diagnose structural changes to the pituitary gland in TBI 
patients. As recommended for pilot studies, we set criteria for acceptable 
completeness of assessments and we considered a >80% completion of 









Descriptive statistics were used to summarise recruitment, retention, data completion 
and baseline characteristics. Means and standard deviations (SDs) were used to 
summarise normally distributed continuous variable and medians and interquartile 
ranges (IQRs) to summarise non-normally distributed continuous variables. 
Percentages were used to summarise categorical variables.  
 
4.4. Results 
A total of 926 patients were screened over 12 month. Participant baseline 
characteristics are presented in Table 1.The median age for this cohort was 63 years 
(IQR43-81years). 
Feasibility measures 
1. Primary outcomes: Recruitment and retention 
Fifty four participants were recruited over the 12 month period. This was a screening 
to recruitment ratio approximately 1 in 17. The most common reasons for failure to 
recruit were potential participants were missed by the research team (33%) and 
because potential participants excluded because they had a normal CT head (26%) 
(figure 3). There was an attrition rate of 72.2% with only 15 of the 54 completing the 
6 month follow-up. Eighteen of the recruited patients (33.3%) were excluded after the 
first visit because of incomplete data or blood sets. Therefore, only 36 of the 54 were 
eligible for follow up at 6 months. Of these 36, the attrition rate was 58%. 
2. Secondary outcomes: Assessments 





All recruited participants returned for their first blood test appropriately fasted. 
Therefore participant completion of this first assessment was 100%. However, there 
were technical problems with processing the blood tests in 18 of 54 participants 
(33.3%) and therefore these patients were excluded from subsequent visits which 
dropped completion of this assessment to 66.6%. There was 100% completion of the 
MRI scans for participants recruited to have MRI. The planned sequences provided a 
detailed examination of the pituitary gland and permitted analysis of structural 
damage. Baseline information was successfully competed for all participants at this 
stage.  
 
b. Follow-up visit 1 (6 months +/- One month after TBI) 
Fifteen of the 36 participants who were eligible for inclusion in the second stage of 
the study attended. Assessment during this stage required participants to have been 
fasted from midnight the night before and also required patients to have intravenous 
cannulation and stimulation testing, which included intravenous injections of 
synacthen, growth hormone, release hormone, and arginine and serial serum 
samples every 30 minutes for three hours. All participants completed this process 
and there were no adverse effects. All participants were able to undergo assessment 
as day cases and none required hospital admission as a consequence of the 
assessments. The GOSE was completed by all 15 participants. 
 
Assessment fidelity 
All assessments were conducted as per the study protocol including all blood tests 





incorrectly leading to exclusion of these patients from the study. This was not within 
the control of the study team.  Finally, a lack of resources led to modification of the 
protocol occurred after the first few patients were recruited and the third study visit 
was omitted. As this occurred after implementation of the pilot study, 0% of patients 
completed this assessment.  
 
4.5. Discussions 
Our results suggest that a large, prospective study to evaluate the prevalence and 
risk of PTPD that aims to recruit patients from the emergency department is feasible. 
One in 17 patients agreed to recruitment into the study from a moderate sized 
emergency department and nearly 1000 patients were screened. The pilot study has 
highlighted the low retention rate in this patient cohort. Positively, the pilot study 
demonstrated strong treatment fidelity with 100% of treatment components and 
study assessments delivered in alignment with the study protocol for all participants 
that attended the study visits. 
Limitations 
1. High attrition 
The high attrition rate from the first to second visit is an important feasibility outcome 
that will have to be addressed in the design of a future definitive study. Attrition rates 
are influenced by patient specific factors and study design factors. Patient factors 
associated with loss to follow-up in TBI include low socioeconomic and ethnic 





attributes are prevalent in TBI populations (table 1). It is therefore difficult to design a 
study that excludes these patients as the results could not be extrapolated for the 
general TBI population.  
One solution, which we adopted during the pilot study, is to reduce the number of 
follow-up visits. Our decision to omit the third visit was, in part, directed by the 
difficulties we encountered whilst trying to organise follow up for patients at this 
stage of the pilot study. A future definitive study will have just a single follow up visit. 
There is no consensus on the optimal timing of assessments in TBI [11]. However, 
there is clear evidence that the longer the duration between assessments, the higher 
the attrition rates. There is also evidence that de novo pituitary dysfunction can occur 
up to one year following TBI [12]. Therefore a reasonable strategy for a definitive 
study is a single follow up at 12 months after TBI. 
2. No control group 
Another criticism of the pilot study was the lack of a control group. There remains 
uncertainty about the clinical significance of post-TBI anterior pituitary dysfunction 
[13]. One way to improve on the evidence is to conduct a prospective study that 
includes a control group of non-TBI trauma patients. This would improve the validity 
of the study and its results. Therefore, definitive future study must have a pre-defined 
control group who are put through the same assessments as the main study group. 





We did not specify how the participants that had MRI scans were selected. This was 
done at random during this pilot phase but will need to be more explicit in the 
definitive study. 
4.6. Conclusion 
The lessons learnt from the pilot study have allowed us to modify the PitSTOP 
protocol to better suit the patient demographic. The results of this pilot study also 
suggest that it is feasible to implement a fully powered case-controlled study to 
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Figure 1. The GANTT chart above shows the overall timeline for the full PitSTOP Study. A line has been added to show the end of 



























Figure 2. Proposed patient flow for PitSTOP participants 
* 20 consecutive patients will be offered an MRI brain scan across each of the 3 
study stages. A total of 20 MRIs will be performed 
** Stimulation blood tests for growth hormone deficiency (GHD) and secondary 
hypoadrenalism 
 
0 – 7 days following TBI 
• Baseline pituitary blood test 





6 months (+/- 1 month) Follow Up 
• Baseline pituitary blood test 
• Pituitary stimulation & blood tests** 
• MRI scan* 




12 months (+/- 1 month) Follow Up 
• Baseline pituitary blood test 
• Pituitary stimulation & blood tests** 




Assess for eligibility by completing Screening 
Data Form. 
          









Figure 3.  Bar graph of PitSTOP participant recruitment. Top bar represents recruited patients and the rest represent reason 














0 5 10 15 20 25 30 35
1 - Declined
2 - inability to  consent
3 - Pre-existing Endocrine Diagnosis
4 - BMI >35
5 - Unlikely to survive the next 24 hours
6 - Epileptic
7 - Medication affecting H-P Axis
8 - Normal CT head
11 - Unclear Diagnosis (organic/pathology)
12 - Missed OOH
13 - Missed in hour (no one able to consent)











































 Female 336 36% 
 Male 377 41% 
 Missing 213 23% 
    
Mechanism of Injury 
 Assault 93 10% 
 Collapse 43 4.6% 
 Fall 489 52.8% 
 RTA 26 2.8% 
 Sports 19 2% 
 Missing 282 30.5% 
    
GCS 
 13 13 1.4% 
 14 133 14.4% 
 15 500 54% 
 Missing 280 30.2% 
    
SIMD    
 1 72 7.8% 
 2 125 13.5% 
 3 106 11.4% 
 4 99 10.7% 
 5 157 16.9% 






















Figure 5. Adapted recruitment flow chart for PitSTOP Pilot 
RECRUITEMENT  
Assessed for eligibility and completed visit 1 (n=54) 
Excluded due to incomplete blood 
processing (n=18) 
COMPLETION OF VISIT 1  
Completion of visit 1 assessments (n-=36) 
Excluded from analysis (n=0)  
ANALYSIS  
Analysis of patient data (n=15) 
COMPLETION OF VISIT 2 
Completion of Visit 2 assessments (n=15) 
Lost to follow up (n=21) 





Outcomes from Pilot Study: Part 1 
Paper Three 
Characteristics of patients presenting with mild traumatic brain injuries 
(mTBIs): Is it time we considered mTBI a different clinical entity to moderate 
and severe TBI? (submitted) 
 
Introduction: 
In order to better characterise traumatic brain injury (TBI) and to identify the most 
effective research approaches for mild TBI, we conducted a study to determine the 
demographics and short-term outcomes in these patients. Information from this study 
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Characteristics of patients presenting with mild traumatic brain injuries 
(mTBIs): Is it time we considered mTBI a different clinical entity to moderate 
and severe TBI? 
Abstract 
Background: 
Little is known about the demographic and clinical characteristic differences of 
patients suffering mild TBI (mTBI) 
Objective: 
To determine the demographics and short-term outcomes of patients presenting to 
the emergency department with significant mild traumatic brain injuries (mTBI) that 
met the SIGN guidelines for CT brain imaging.  
Methods:  
Prospective study of consecutive trauma admissions to a level 1 trauma hospital. We 
compared differences in mechanism of injury, injury severity and 30-day outcomes 
between different groups including between male and female patients, different age 
groups and different socioeconomic groups for a final total of 709 patients.  
Results:  
The average age of patients was 63 years and 47% of patients were female. There 
was a male predominance in younger patients, but this disappears by the middle 
ages and the number of elderly female patients exceeded the number of elderly male 
patients. Young patients were more likely to be from lower socioeconomic areas, 




length of stay in hospital was 0 days and patients intoxicated with alcohol were 
discharged earlier than those not intoxicated. There was only one death and 
therefore a mortality of 0.14% in this cohort  
Conclusions:  
The demographics, injury characteristics and outcomes for mTBI are different to 
moderate and severe TBI. mTBI should be considered a different disease entity with 


















Major trauma is the leading cause of death and disability of people under 40 years 
old (1) and in this age group, traumatic brain injury (TBI) is prevalent. TBI has been 
described as a “silent epidemic” that affects approximately 1.5 million people a year 
in England and Wales each year (2). In the last 4 decades, protocol-driven 
treatments of acute TBI, such as the Advanced Trauma Life Support (ATLS) and 
National Institute for Health and Care Excellence (NICE) protocols (3,4), have 
improved outcomes and reduced mortality for patients who sustained moderate and 
severe TBIs (5,6,7). But these patients form only 10-20% of TBI patients. Patients 
with mild TBI (mTBI), usually defined as a post-resuscitation Glasgow Coma Score 
(GCS) of 13 to 15, are much more prevalent (8,9). We know less about the 
epidemiology and outcomes of mTBI due to differences in patient pathways across 
different hospitals and because only few patients are followed up by specialists (10). 
  
In the last decade, several large scale, multisite studies have been set up to address 
this historic oversight (11). Protocols such as those provided by NICE and the 
Scottish Intercollegiate Guidelines Network (SIGN) have also been modified to help 
with decision making in the acute management of mTBI such as in determining 
which patients should have imaging of their brains and which ones should be 
observed in hospital (12). But these guidelines have a limited role in the overall 
management. There needs to be a better understanding of this patient group and 
their clinical needs. The objective of this study was to describe the demographics, 
clinical characteristics and short-term outcomes of patients that present to the 




scan. We describe gender, age and socioeconomic differences and assess the 




Our analyses are based on individual patient data from the Pituitary dysfunction in 
TBI: Outcomes and Prevalence (PitSTOP) feasibility study (currently unpublished). 
In this study, patients presenting within a week of sustaining an isolated mTBI to the 
emergency department at the Royal Infirmary of Edinburgh, Scotland, were screened 
and when suitable, recruited for follow up pituitary function tests within one week and 
six months following mTBI. We defined mTBI as an alteration in brain function, or 
other evidence of brain pathology, caused by an external force and resulting in a 
post-resuscitation GCS of 13 to 15 (13). Eligible patients were adults (≥17 years old) 
that met the SIGN guidelines for a CT scan of the brain following TBI (12).  
 
We collated data on gender, age, Scottish Index of Multiple Deprivation (SIMD) 
rankings, mechanism of injury and whether alcohol was involved, results of CT scan, 
length of stay (LOS) in hospital (days), admissions to high dependency or intensive 
care units. The SIMD ranking is a measurement of material deprivation that is based 
on an administratively collated data and is created using seven different domains to 
score geographies in Scotland on their relative deprivation. These are income, 
health, crime, employment, education, access and housing. The overall SIMD rank is 
a weighted sum of the 7 domains (14). These domains are used to rank populations 




patient populations according to SIMD quintiles with 1 being the most deprived and 5 
being the least deprived. 
 
Each patient’s GCS and the clinical indication for CT brain was determined by and 
documented by their responsible emergency department physician.  CT brain 
imaging was categorised according to Marshall CT Classification based on the report 
provided by an independent consultant radiologist with no affiliation to the research 
study. The Marshall CT classification categorises injuries as different levels of diffuse 
lesions, based on basal cistern compression and midline shift, or focal lesions, 
depending on whether lesion volume exceeds 25 cm (table 1) (3,15). This 
classification is still considered a “gold standard” for TBI classification as 
components of the Marshall CT classification have been shown to contribute to 
outcome prediction in TBI (16). The mechanism of injury was determined from the 
description in the medical records as: a fall, road traffic accident, assault, sport and 
recreational activity, collapse or other cause (not defined). Simple cross-tabulations 
and percentages were used to describe the study demography, injury mechanisms 
and features of the care such as CT Marshall Score and duration of admission. 
 
Statistics 
Descriptive data are presented as medians (with interqauntile ratios (IQRs). 
Differences between groups and between subgroups, such as different injury 
severities, were analysed using non-parametric tests (chi-square, Wilcoxon or 
Kruskal–Wallis). Relationships between variables were analysed with the Spearman 




3.2.2 (R Foundation for Statistical Computing). Exact significance levels are given for 
values in the range 0.01–0.05, whereas <0.01 represents significant levels less than 
0.01. P values above 0.05 are considered statistically not significant (NS). 
 
Ethical Approval 
This study was approved by local Caldicott Guardian (reference number 18173). It 
was determined that anonymised patient data could be collected and stored without 
specific patient consent. All data arising from this study were stored on NHS servers. 
The computers on this network have restricted physical access; data are stored 
under coded filenames and the local network has secure password access restricted 
to only the research team. Patients included in the PitSTOP study were consented 
separately (data currently unpublished). Data from those patients are also included 
in this study. 
 
Patient and public involvement 
Patients were not involved in the design of this study, the choice of the outcome 
measures, or analysis of the data or dissemination. 
 
Results 
Age of presentation and the influence of gender 
Between April 2017 and July 2018, a total of 1092 patients were screened as part of 




were omitted from our final analysis. Ultimately, 709 patients (335 females and 374 
males) were included for analysis.  There was a significant difference between the 
age of presentation for female and male patients (p<0.01). The median age of 
presentation for women was 73 years (IQR 50 to 85 years) and the median age for 
men was 50 years (IQR 32-74 years). The overall median age of presentation for 
men and women was 63 years (IQR 38-81 years). The number (and proportion) of 
patients in each age group (categorised according to decade of life) are shown in 
table 2. Octogenarians were the largest age group represented and constituted 23% 
of all patients. The number of patients in this group was nearly double the second 
biggest group, which were patients in their twenties (13.9%).  Septuagenarians were 
the third largest age group represented (13.8%).  
 
There was a bimodal distribution of age of presentation for both men and women. 
For men, the two peaks of the bimodial curve were at 30 and 60 years. For women 




and then a much larger peak at 70 years. This was much larger than the second 
peak seen for men. Before the age of 50, there was a male predominance in patients 
presenting with mTBI. This predominance lessened as the age of presentation 
increased until the age group 50-59 years, when there was an equal number of male 
and female patients. In septuagenarians, octogenarians and nonagenarians, the 
proportion of female patients presenting with mTBI exceeds male patients. The 
female representation in these groups was large enough to counter the male 
predominance in younger age groups such that the overall female proportion in all 
age groups (47%) was almost the same as males (figure 1). 
 
Mechanism of injury in each age group  
The most common causes for mTBI were falls and assaults, accounting for 69% and 
14%, respectively. Road traffic accidents (RTAs) and collapses (of unknown origin) 
occurred less frequently (table 2). Generally, the proportion of patients presenting 
with assaults decreased with age whilst the proportion presenting as a result of a fall 
increased with age. Approximately one-third of patients under 30 years presented 
following an assault whilst nearly one-fifth of octogenarians (the largest group 
represented) presented following a fall. The proportion of patients presenting 
following a sports injury followed a unimodal distribution which peaked in the age 
group 30 to 39 years old. The highest incidence of RTAs were seen in patients less 
than 30 (14%) and in patients between 50 and 59 years old (10%) (table 2). 
 




a. Marshall CT score 
The majority of patients a Marshall CT score of 1 (649 patients; 92%) or 2 (50 
patients;7%).  There were no gender differences between CT Marshall scores 
(p=0.73). The median lengths of hospital stay for patients with Marshall CT 
groups 1 and 2 were 0 (IQR 0-1 days) and 2 days (IQR 1-2 days). The 
median LOS for patients with CT Marshall score 3 and 4 were 23 days (IQR 
12.5-87.5 days) and 6 days (IQR 4-22.5 days). One patient had a CT Marshall 
score of 5 and was hospitalised for 33 days and three patients had a CT 
Marshall score of 6. One died and the other two were in hospital for an 
average of 18 days. 
   
b. Fractures 
There were a total of 34 (4.8%) skull fractures (19 facial fractures and 15 
cranial vault fractures). There were 3 patients (0.42%) with associated 
cervical spine fractures. Two of these were odontoid peg fractures. Patients 
with no skull fractures (median age = 64 years (IQR 39-82 years) were 
significantly older than patients with fractures (median age 43 (IQR29-73; 
p<0.01). The median LOS for patients with c-spine fractures (9 days) was 
longer than for all without c-spine fractures. 
 
Anticoagulation and antiplatelet medications 
There were 253 patients (35.7%) patients on antiplatelet or anticoagulation 




the proportion of males (28.7%; p<0.01). The proportion of patients on these 
medications increased with age (table 2). The median age was significantly higher 
for patients on anticoagulation or antiplatelets. The median age for patients on these 
medication was 80 years (IQR 71-87 years) compared to a median age of 46.5 years 
(IQR 71 to 87 years) for patients not on these medications (p<0.01). The medications 
included clopidogrel (28.1%), Apixiban (23.3%), aspirin (21.7%) and warfarin 
(18.6%). There was no difference in the median LOS between patients on 
anticoagulation or antiplatelets and those that no were not on these medications 
(median number of days = 3 days (IQR2-18 days) vs 2 days (IQR 2-4); p=0.06). 
There was also no difference in median Marshall CT score for patients on 
anticoagulation &/or platelets and patient not on these medications.  
 
Socioeconomic status 
The proportion of female and male patients in each SIMD quintile were similar. There 
were 13.3% patients from SIMD quintile 1 (44% females, 56% males); 21.4% from 
quintile 2 (49% females and 51% males), 18.7% from quintile 3 (44% females and 
56% males), 17.8% from quintile 4 (49% females and 51% males) and 28.7% from 
quintile 5 (52% females and 48% males). Generally, the average age of patients 
increased with SIMD. There was a higher proportion of young patients in SIMD 
quintiles 1 and 2 (most deprived) and a higher proportion of older patients in SIMD 4 







Influence of alcohol 
Alcohol intoxication (patient reported alcohol use immediately prior to TBI) was 
recorded in 27.5% of patients. Patients in whom alcohol involvement was recorded 
were significantly younger than those in whom alcohol involvement was not recorded 
(46.3 years vs 65.7%; p<0.01). Alcohol involvement was recorded in two-fifths to half 
of patients up to 70 years old. The proportion of patients who were intoxicated with 
alcohol then falls markedly (table 2). Alcohol involvement was significantly less likely 
with female patients than with male patients: one-fifth (20.4%) of female patients 
compared with nearly two-fifths (37.7%) of male patients were intoxicated at the time 
of presentation (p<0.01). LOS was shorter for patients in whom alcohol involvement 
was recorded compared to those in whom alcohol involvement was not recorded 
(1.58 days compared to 4.24 days, p<0.01). 
 
Length of stay in hospital, thirty day readmissions and death 
The median LOS was 0 days (IQR 0-2 days). There were no difference in the 
median length of stay between male and female patients (p=0.4) or between patients 
from different social status (p=0.8). There was a weak correlation between age and 
LOS. The correlation coefficient was 0.11 [95% confidence interval 0.07 – 0.15] 
(p<0.01) (figure 4). Sixty percent of patients were discharged on the same day of 
admission and 84% of patients were discharged within 2 days of admission. Only 74 
patients (10.4%) were admitted for longer than 7 days. No patient was referred to a 





There were 99 (14%) readmissions within 30 days of initial discharge. The majority 
of these were due to planned outpatient follow up appointments with specialists for 
management of associated injuries such as maxillofacial surgery for those who 
sustained facial fractures and follow up with physicians for patients who had 
unexplained collapses. The highest rates of readmissions were seen in patients in 
their 70s and 80s. There was only one death; a death rate in this cohort of 0.21%. 
The patient was an 84-year-old who took Apixaban and whose SIMD quintile was 3. 
She presented with a post-resuscitation GCS of 14 and a Marshall CT score of 6 (a 
subdural haematoma that was not evacuated). She died several days after discharge 
from the emergency department.  
 
Discussion 
TBI is often considered a disease of young men. However, our findings have 
highlighted that this is not the case for mTBI. We have shown that mTBI, unlike 
severe and moderate TBI, affects older patients more than younger patients; 
approximately 62% of patients with mTBI that met the SIGN guidelines for CT brain 
were 50 years or older. We have also found that above the age of 50, the male 
predominance typically described for TBI, disappeared and there was a female 
predominance. There was an approximately 50:50 split of male and female patients 
in the 50-59 and 60-69 age groups. As with moderate and severe TBIs, the 
mechanism of injury changes as patients get older with younger patients more likely 
to be assaulted or involved in RTAs and older patients more likely to present due to 




of patients presenting as a result of RTAs was small. This has previously been 
demonstrated by others and corroborates the lower impact trauma usually reported 
in mTBIs (17,18). It also explains the low mortality of mTBI compared with the high 
mortalities seen with moderate and severe TBIs (19).  
 
One explanation for the average age of patients included is that the SIGN guidelines 
for CT brain imaging recommend scanning all patients over the age of 65 years with 
any loss of consciousness or amnesia and all patients on anticoagulation and with 
neurological deficits. Such measures, designed to identify elderly patients at risk, 
inevitably lead to a disproportionately higher number of elderly patients getting CT 
brain imaging. 
It is interesting that younger patients that sustain mTBI are more likely to be from 
less affluent areas and the opposite is true for older patients. The reason for this is 
unclear but it may be that young people in less affluent areas are more prone to high 
risk behaviours than their counterparts in more affluent areas and conversely, older 
patients from affluent areas may be more likely to keep their independence for longer 
and therefore be more prone to falls and accidents. Furthermore, people in more 
affluent socioeconomic geographies live longer and therefore are likely to have a 
higher proportion of elderly representatives that less affluent areas. 
 
Alcohol played a role in approximately one-third of presenting patients and was twice 
more likely to have played a role in male patients than in female patients. A similar 




moderate and severe TBIs (20). Alcohol use is a known risk factor for all types of 
injures and mTBI is seemingly no different (18). Patients in whom alcohol 
involvement was recorded were in hospital, on average, half the number of days of 
patients in whom alcohol involvement was not recorded. Presumably, this is because 
younger patients were more likely to be intoxicated and are discharged from 
emergency departments once they become sober. 
 
None of the patients in our cohort were referred to a specialist head injury service 
after discharge. One possible reason why our understanding of mTBI has been 
extrapolated largely from moderate and severe TBI research is that many patients 
with mTBI are managed in and discharged from  emergency departments and do not 
get seen by or followed up by experts and therefore very little is known about the 
outcomes for these patients. In a recently study, Nelson and colleagues reported that 
over 80% of mTBI sufferers reported a functional impairment at 12 months and that 
approximately half of mTBI sufferers reported functional limitations. However, most 
did not receive follow up care after discharge from the emergency department (21). 
This seems to be commonplace in many emergency departments across Europe 
(11). 
 
Nelson and colleagues also demonstrated in their study that patients with acute 
intracranial findings were more likely to suffer neuropsychological sequalae. It may 
be that patients with Marshall CT classification >1 are at greater risk of complications 
and should be admitted for longer and perhaps should be offered follow up after 




evidence that higher Marshall CT scores was associated with increased 
readmissions within 30 days of discharge. It should be noted that the Marshall scale 
was designed as a predictive tool for patients with moderate and severe TBIs that 
were likely to develop raised ICP. It is therefore has limited used in mTBI.  
 
One potential challenge with mTBI research and the clinical approaches to these 
patients is that they are numerous. mTBI is a common diagnosis and constitutes 
approximately 80% to 90% of TBIs. The true prevalence is not known because a 
number of patients either do not present to hospital or do not get a diagnosis of TBI. 
It would be difficult to offer follow up to all patients presenting with mTBI and more 
pragmatic measures and guidelines for follow up are needed to in order to make the 
economics of patient follow up viable. An example of this is the emerging evidence 
that some TBI sufferers develop anterior pituitary gland dysfunction that is 
undetected and that may contribute to long term neuropsychological symptoms (22). 
It would be economically and logistically difficult to offer every patient presenting to 
the emergency department with mTBI pituitary function tests and also to ensure that 
all patients with abnormal pituitary results are seen by an appropriate specialist. 
Further research is needed to identify those patients at risk and to help formulate 
surveillance guidelines.   
 
Limitations 
One limitation of this study is the inclusion of only mTBI patients that met the SIGN 




criteria designed to ensure that “trivial” TBIs were not included, it is likely that some 
patients with significant injuries that presented to the emergency department did not 
meet the criteria for brain imaging and therefore were not included. Consequently 
our findings may not be an accurate reflection of outcomes of mTBI patients. 
Secondly, although it was not part of our objective, there was perhaps a missed 
opportunity to follow these patients up for long term outcomes (> one month). 
Recently, published data suggests that patients with CT-positive mTBI are more 
likely to report difficulties with activities of daily living. With so few large series on this 
patient group, additional information about long term outcomes would have been a 
useful contribution to the current literature. 
Conclusions 
Despite its limitation, the data presented is one of the largest cohorts on this patient 
group. We have shown, prospectively, that the patient characteristics of mTBI are 
different to the traditional understandings of TBI that has largely been determined in 
patients with moderate and severe TBI. There is a potential danger of extrapolating 
the results from the research focused on moderate and severe TBIs to this patient 
group. Researchers and clinicians should view mTBI as a different clinical entity to 
severe and moderate TBIs and further research is needed to better understand the 
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Figure 1. Density plot of age distribution for female and male patients. The proportion 
of female TBI patients becomes equal to males by their mid-50s and subsequently 










Figure 3. Bar plot of SIMD quintiles for each age group (Scottish Index of 











Figure 4. Scatter plot (a) and bar plot (b) of age against length of stay showing 





Marshall CT Classification Radiological features 
I No visible pathology 
II Midline shift of 0 to 5mm 
Basal cisterns remain visible 
No high or mixed density lesions > 25cm3 
III Midline shift 0 to 5mm 
Basal cisterns compressed or completely effaced 
No high or mixed density lesions >25cm3 
IV Midline shift >5mm 
No high or mixed density lesions >25cm3 
V Any lesion evacuated surgically 
VI High or mixed density lesions >25cm3 
Not surgical evacuated 
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The results showed that mild TBI affected a different patient demographic to that 
reported for moderate and severe TBI. Unlike with moderate and severe TBI, mild TBI 
affected older patients. I also found that this patient group had a very short hospital stay. 
This study led to me altering the PitSTOP protocol to allow the first visit to occur within 7 
days of TBI as I now knew that most patients were discharged on the same day and 























Outcomes from Pilot Study: Part 2 
Paper Four 
Anterior hypothalomo-pituitary dysfunction occurs in mild Traumatic Brain 
Injuries without evidence of structural damage to the pituitary gland: Results 




During this feasibility study, all aspects of the PitSTOP protocol are tested with a 
focus on patients with mild TBI. The results of study will determine how workable the 
PitSTOP protocol is and whether it can be rolled out as a multi-centre study. We will 
also aimed to determine whether anterior pituitary dysfunction occurred in patients 
















Anterior hypothalomo-pituitary dysfunction occurs in mild Traumatic Brain 
Injuries without evidence of structural damage to the pituitary gland: Results 
of a pilot study 
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The aims of this study are to examine the acute biochemical and radiological 
response of the anterior pituitary to acute mild traumatic brain injury (mTBI) and to 
determine the prevalence of post-TBI anterior pituitary dysfunction (PTPD) six 
months following mTBI. 
 
Methods:  
Patients presenting to the ED with mTBI (GCS 13-15) were screened with a fasting 
morning serum levels of cortisol, free thyroxine, TSH, prolactin, IGF-1 and sex 
hormones and an MRI scan of the pituitary gland within 7 days of injury and were 
followed up at 6 months repeat anterior pituitary blood test including stimulation tests 
and a repeat MRI. 
 
Results:  
A total of 36 patients completed baseline anterior pituitary hormone serum blood 
test. (within 7 days of mTBI). There was abnormal hormone activity in 44% (16/36). 
All had abnormalities in a single anterior pituitary axis and none had deficiencies in 
multiple axes. Only elevated serum cortisol correlated positively with injury severity 
on CT. Fifteen patients returned for follow up at 6 months and 3 (20%) were found to 
have PTPD. There was no association between anterior pituitary dysfunction and 







Pituitary dysfunction occurs after mTBI and is not caused by structural damage of 
the pituitary gland.  
 




















Traumatic brain injury (TBI) remains a leading cause of adult mortality and morbidity 
in the developed world1.  Many sufferers do not return to their pre-injury level of 
function and quality of life because of ongoing physical or neuropsychological 
disabilities2. Some symptoms may be due to post-TBI anterior pituitary dysfunction 
(PTPD)3 4. PTPD is defined as evidence of anterior pituitary dysfunction attributable 
to TBI and occurring at least 3 months following TBI. This is distinct from anterior 
pituitary hormone changes that occur in the days following TBI5 6 7 8 9. Several meta-
analyses have concluded that PTPD occurs in approximately one-third of TBI 
suffers4 10 11. It has been difficult to determine whether abnormal pituitary function 
following acute TBI is pathological or is an appropriate adaptive response to the 
injury and whether it predisposes to PTPD. The mechanism of PTPD is also unclear 
and there are several hypotheses including direct damage to the anatomically 
vulnerable pituitary gland from the primary injury1213 and secondary insult due to 
oedema, haemorrhage or hypotension14 15. These hypotheses have been largely 
extrapolated from post-mortem studies of patients who died from TBI and there are 
only a small number of studies that have used magnetic resonance imaging (MRI) to 
assess the pituitary gland of patients that suffered acute TBI. For example, Maiya 
and colleagues demonstrated pathological changes in the pituitary gland during the 
acute phases following moderate and severe TBI16 and Zheng and colleagues 
demonstrated, using apparent diffusion coefficient (ADC) MRI imaging, that 







Most studies on PTPD have been focused on patients with moderate and severe 
TBI. These patients have serious and often catastrophic physiological insults which 
may include anterior pituitary dysfunction. Mild TBIs (mTBIs) damage brain cells and 
trigger the same damage associated molecular patterns (DAMPS) seen in moderate 
and severe injuries without necessarily triggering the same systemic responses seen 
in moderate and severe TBI18. It can therefore be hypothesised that the anterior 
pituitary response to isolated mTBI may reflect the true response to TBI without 
being confounded by the global and systemic responses to injury that occur in 




Some of the long-term consequences of TBI are due to DAMPS occurring during the 
acute phase of the injury which may persist or progress. There have been 
suggestions that screening for PTPD should be offered to patients who sustain 
“complex” mTBI; defined as intercranial bleed, brain swelling or skull fracture on 
initial computerised tomography (CT) scan. Therefore, the  aims of this study are 
firstly to determine how mTBI affects the structure and function of the anterior 
pituitary gland acutely, secondly to prospectively determine the prevalence of PTPD 
at 6 months following mTBI, and finally to establish whether acute pituitary hormone 





Material and methods 
 
Patients  
This study reports on individual patient data from the Pituitary dysfunction in TBI: 
Outcomes and Prevalence (PitSTOP) feasibility study. In this study, patients 
presenting within 7 days of sustaining an isolated mTBI to the emergency 
department (ED) at the Royal Infirmary of Edinburgh, Scotland, were screened and 
when suitable, recruited to have baseline serum test of anterior pituitary gland 
function and MRI scan of their pituitary gland within one week of injury. They were  
then followed up at six months with stimulation (growth hormone and 
adrenocorticotropic axes) and baseline (all other axes) testing of anterior pituitary 
gland function, and a further MRI scan of their pituitary gland. We defined mTBI as 
an alteration in brain function, or other evidence of brain pathology, caused by an 
external force and resulting in a post-resuscitation Glasgow Coma Scale (GCS) 
score of 13 to 1519. We kept patient selection criteria broad; eligible patients were 
adults (≥17 years old) that met the National Institute for Health and Care Excellence 
(NICE) guidelines for a CT scan of the brain following TBI20.  
 
We collated data on gender, age, body mass index (BMI), mechanism of injury and 
results of CT scan. Each patient’s GCS and the clinical indication for CT brain was 
determined by and documented by their responsible ED physician.  CT brain imaging 




who had evidence of haemorrhage or skull vault or base of skull fractures on CT 
scans were deemed to have a ‘complex’ mTBI, in order to differentiate from those 
whose index scans were normal (non-complex mTBIs)22. The mechanism of injury 
was determined from the description in the medical records as: a fall, road traffic 
accident, assault, sport and recreational activity, collapse, or other cause (not 
defined). Simple cross-tabulations and percentages were used to describe the study 
demography, injury mechanisms and features of the care such as CT Marshall Score 
and duration of admission. 
 
Many medications can affect pituitary function including several medications used in 
the acute setting. For example, opiates act with varying potency at three types of 
receptors (gamma, kappa and mu) and have varying effects on the pituitary gland. 
Most research has focused on opioid-induced hypoginadism but emerging evidence 
suggests that they can also cause adrenal insufficiency. Other commonly used 
medications including antidepressants, antipsychotics, antihistamines, and proton-
pump inhibitors can raise prolactin levels. A list of medications that may affect HP-
axes were approved by an endocrinologists and patients on these medications were 
excluded for the study. We used the following exclusion criteria: 
1) Patients with a pre-existing endocrine diagnosis 
2) Morbidly obese patients with BMI >35 
3) Unlikely to survive for the next 24 hours in the opinion of the intensive care or 
neurosurgical team treating the patient 




5) Patients on medications that are known to affect the hypothalamic-pituitary axis 
6) Patients who are not able to consent 
Written informed consent was sought from all participants recruited to the study. 
 
Serum Hormone Measurements 
Anterior pituitary dysfunction was defined as the presence of single or multiple 
anterior pituitary axes deficiencies. These were based on the normal serum 
concentrations of hormone as defined by our local laboratory and include:  
1. serum prolactin level 60-500mIU/L (22 ng/ml) 
2. gonadotropin deficiency was defined for women as secondary amenorrhea or 
a menstrual disorder with a blood oestradiol level below 20 pg/ml and normal 
or low gonadotropin levels and for men as a blood testosterone level below 10 
nmol/L with normal or low gonadotropin levels.  
3. Thyrotropin deficiency was defined as a low free thyroxine (T4) level with 
normal or low thyroid-stimulating hormone (TSH) levels.  
4. Acute corticotropin deficiency was defined as a blood cortisol level below 
138μg/dl. To determine corticotrophin deficiency at 6 months, a short 
synacthen test (SST) was performed: 250μg of synacthen was administered 
intravenously and cortisol levels were checked before and after 30 minutes. 
Cortisol level of <430 nmol/L were regarded as deficient. 
5. Growth hormone (GH) axis was assessed after acute TBI using baseline 
insulin-like growth factor 1 (IGF-1) levels. Normal levels were between 72 and 
259μg/L GH axes at 6 months was investigated with GH releasing hormone 




bolus injection, immediately followed by infusion of an arginine solution 
(0.5g/kg) over 30 minutes. Serum GH was measured at baseline, 30, 60, 90, 
120 and 150 minutes. The following cut-off levels were used to diagnose GH 
deficiency (GHD): for patients with a BMI < 25 a peak GH < 11.5ng/L, for BMI 
of 25–30 a peak GH < 8.0ng/L, and for patients with BMI > 30 a peak 
GH < 4.2ng/L. 
MR Imaging Protocol 
MRI scans have greater soft tissue contrast allowing for better visualisation of the 
pituitary gland than CT imaging. Therefore, a T2w whole brain volume and T1w and 
T2w saggital and coronal views of the sella region were acquired. All participants 
were imaged using a Siemens Magnetom Prisma 3 T clinical scanner (Enlangen, 
Germany). Images were loaded onto the hospital PACS system and interpreted by a 
consultant radiologist (AF). 
 
Statistical Analysis 
Patients’ data were expressed as median (interquartile ranges) if non Gaussian 
distribution or mean ± SEM if Gaussian. Normally distributed values between two 
variables were compared by unpaired Student’s t test, with a 95 % confidence 
interval (CI), whereas the Mann–Whitney U test was performed for non-parametric 
data. The chi square test or variance analysis was used to compare categorical data. 
Correlations were tested with Pearson test. Statistical significance was considered 
when the P value was <0.05. All the statistical analyses were carried out using R, 





Ethical approval  
 
The studies that provided data for evaluating this protocol were approved by the 
Lothian Ethics of Medical Research Committee (REC 17/SS/0043) and the NHS 
Lothian R+D Office (2017/0146), and conducted according to the principles 
expressed in the 1964 Declaration of Helsinki. All patients gave written informed 
consent to be included in the study. 
 
Results  
A total of 54 patients consented for inclusion in the study. A complete anterior 
pituitary profile was not completed in 17 patients; these patients were omitted from 
the final analysis as well as 1 patient who did not return for blood tests.  A total of 36 
patients (21 female and 15 males) were included in the final analysis.  The median 
age for this cohort was 38.5 years (IQR27.5-59.5 years) and the median BMI was 24 
(IQR 22-27). There were 28 patients (80%) that presented with mTBI following a fall, 
4 patients (11.4%) following an RTA and 2 patients (5.7%) that presented following 
an assault. Two patients (5.7%) presented following sports injuries. Three patients 
had a post resuscitation GCS of 13, 6 patients had a post resuscitation GCS of 14 
and 27 patients had a post resuscitation GCS of 15.  
 
A. Acute anterior pituitary response to mTBI 
Sixteen patients (44.4%) had at least one anterior pituitary axis dysfunction in the 




which 5 were elevated and one was low, 5 patients (13.8%) with hypogonadism, 5 
patients (13.8%) with hypercorticolsaemia, one patient (2.8%) with 
hyperprolactaemia and one patient (2.8%) with low thyroid function.  
 
The median age for patients with acute anterior pituitary hormonal abnormalities was 
33 years (IQR 26.5-43.5 years) compared to 45.5 years (IQR 29-67.5 years) for 
those with normal hormone profile and the median BMI for patients with abnormal 
and normal hormone profiles were 24.5 and 24, respectively. There were no 
significant differences in age or BMI for patients with abnormal and normal pituitary 
profiles (p=0.67 and 0.66, respectively). There were also no differences between the 
proportions of participants with “complex” and non-complex mTBIs. 
 
Elevated cortisol levels 
Serum cortisol levels are usually elevated as a response to stress. Five patients 
(13.8%) had elevated cortisol levels in the first week following TBI. Four of the five 
were patients who had sustained mTBI following falls. One patient had a sports 
injury. Four of the 5 were female. There was no difference between BMIs of patients 
with elevated serum cortisol (BMI 22[IQR 21-24]), compared to patients with normal 
serum cortisol concentrations (24.5 [IQR 22-27.5] (p=0.29).  There was also no 






The median serum cortisol concentration for the cohort was 379.5nmol/L (IQR 277.5 
to 503.5nmol/L). Patients with complex mTBIs had a significantly higher median 
cortisol concentration than patients without complex mTBI (462nmol/L vs. 
351.5nmol/L; p=0.035). However, there were no differences in serum cortisol 
concentrations between female and male patients (p=0.14), patients with normal and 
abnormal pituitary profile (p=0.4) or between the different mechanisms of injury 
(p=0.38).  There was an inverse correlation between post resuscitation GCS and 
serum cortisol concentration, but this was not significant. There was no significant 
correlation between age and cortisol concentration and no correlation association 
between BMI and cortisol concentration.  
 
Somatotrophic-IGF-1 axis  
 
IGF-1 levels were available for 32 patients. Six patients (18.75%) had an abnormal 
somatotrophic axis; five had elevated IGF-1 levels and one male patient had a low 
concentration. Four of the six had suffered a mTBI following a fall, one had an RTA 
and one was assaulted. There was no difference in the mean ages (43.1 years 
(abnormal GH) vs. 45.4 years; p=0.8) or BMI (p= 0.26) between the patients with a 
normal and abnormal somatotrophic axis (Table 1). There was no significant 
difference in the mean IGF-1 concentrations between patients with and without 






Gonadotrophic axis  
 
Sex hormone assays were available for 32 patients (13 female and 19 male). Nine 
patients (28.1%) had hypogonadism. All were male and therefore 47.4% of males in 
this cohort had hypogonadism. Males were therefore significantly more likely to 
suffer hypogonadism post mTBI than female patients (p=0.01).  There were no 
differences in the ages (p=0.26) and BMIs (p=0.1) of patients with and without 
hypogonadism and there was also no difference in the proportions of patients with 
and without complex mTBIs in each group. 
 
Thyrotrophic axis and prolactin 
 
Thirty-six patients had blood tests to check the thyrotrophic axis. Only one female 
patient had serum tests compatible with hypothyroid. The same patient had a raised 
serum prolactin and was the only participant with abnormal serum prolactin levels. 
This patient was subsequently found to be taking oral contraceptive pill that affected 
both these pathways and was subsequently excluded from the study. No patient had 








Thirteen patients (9 females and 4 males) consented to having MRI imaging within a 
week following mTBI. Four of the 9 female patients had an abnormal pituitary axis 
(one had 2 abnormal axes) and all 4 males had an abnormal axis (3 had 
hypogonadism and one had a raised IGF-1). The gross structures of the anterior 
pituitary in all patients scanned were normal and there was no evidence of structural 
anterior pituitary gland damage.  
 
B. Chronic anterior pituitary response to mTBI 
Fifteen of the 36 patients (42%) returned for follow up anterior pituitary testing at 6 
months including stimulation tests for growth hormone axis and secondary 
hypoadrenalism. Three (20%) of the 15 returning patients (2 female and one male) 
had evidence of anterior pituitary dysfunction. The male patient had evidence of 
hypogonadism which had persisted from the acute phase of injury and the two 
female patients had evidence of de novo secondary hypoadrenalism: one female 
patient aged 59 years had a baseline cortisol of 268nmol/L and a cortisol of 
395nmol/L 30 minutes after stimulation. The other was 39 and had a pre stimulation 
cortisol of 185nmol/L and post stimulation cortisol of 415nmol/L.  The mechanism of 
injury in all 3 patients was fall. The 59 year old female patient had a complex mTBI 
with a thin subdural haematoma on their index CT scan whilst the other two patients 
did not have any abnormalities on their index CT scan. There was no significant 
correlation between complex mTBI and PTPD. None of the three patients with PTPD 






MRI pituitary at 6 months 
Six of the 13 patients (46%) that had MRI scans within 7 days of mTBI returned for 
follow up imaging at 6 months. One patient, whose pituitary gland was normal at the 
time of injury, had loss of volume of pituitary at 6 months. This patient did not have 
corresponding biochemical evidence of anterior pituitary dysfunction. The rest of the 
patients imaged at 6 months had normal pituitary glands. 
 
Discussions 
There have been disagreements about the clinical significance of PTPD with 
different authors drawing different conclusions about the disease burden23. Our aims 
in this study were to determine the acute biochemical and structural response of the 
anterior pituitary gland to mTBI and the prevalence of PTPD at 6 months following 
mTBI. Our main findings are firstly that there was a high prevalence (44%) of 
abnormal serum concentrations of anterior pituitary hormone in the acute phase 
(within one week) of mTBI, secondly that PTPD occurred in one-fifth of patients 
followed up at 6 months including de novo PTPD in patients previously found to have 
a normal anterior pituitary function, and thirdly these changes occurred without 
associated structural changes on MRI. Only one patient had structural changes in 
their pituitary gland and this was not associated with abnormal hormone activity. To 
our knowledge, this is the first study that attempts to correlate the biochemical 
response of anterior pituitary with structural imaging of the pituitary gland in patients 





We chose to study patients with isolated mTBI because moderate and severe TBIs 
are often associated with severe systemic responses that make it difficult to perform 
or interpret anterior pituitary function.  
 
Pituitary (dys)function following acute mTBI 
1. Adrenal insufficiency 
Several studies have concluded that TBI induces adaptive changes in the HPA axis 
leading most commonly to hypercortisolaemia. However, most have focused on 
reporting the incidence of post-TBI hypopituitarism (PTHP) and in particular, the 
potentially life-threatening hypocortisolaemic24. The reported incidence of TBI-
induced adrenal insufficiency varies widely amongst different studies because of the 
different diagnostic criteria and study protocols used. For example, the gold standard 
insulin-tolerate test is thought to be unsuitable in patients with head injuries because 
of the theoretical risk of seizure15 and the synacthen (corticotrophin) test can be 
unreliable in the acute setting5. Only a small number of studies have reported on the 
acute changes in the HPA axis that occur following mTBI. One such study by 
Tanriverdi and colleagues reported that the HPA response to TBI was similar in 
patients with mTBI compared to those with moderate and severe TBI. The authors’ 
definition of ACTH deficiency was similar to ours and in their cohort of 52 patients, 
9.8% of participant with TBI had evidence of adrenal insufficiency. Similarly, Klose 
and colleagues performed stimulation tests in the first 12 days following TBI in a 
cohort that included 22 patients with mTBI. Two of the 22 mTBI patients (9.1%) had 





In our cohort, none of the participants had hypocortisolaemia and 13.8% of 
participants had elevated serum cortisol levels. Hypercortisolaemia correlated 
positively with injury severity as determined by presence of haemorrhage or fracture 
on CT scan (complex mTBI). The other hormonal changes seen in the acute stages 
in our cohort occurred independent of age, BMI and mechanism of injury. 
Hypercortisolaemia in these patients is therefore likely due to physiological activation 
of the corticotrophin axis in response to stress25. Kleindeinst and colleagues found 
elevated levels of urinary free cortisol and cortisone on day-7 in 85% of patients 
tested, concluding that the normal circadian variation of cortisol is replaced by a 
more continuous secretion under severe stress26. Additionally, hypercortisolaemia in 
our cohort occurred without any structural damage to the pituitary gland on MRI scan 
suggesting it is physiological and not pathological. On this basis we found that in the 
setting of mTBI, acute adrenal insufficiency does not occur and there is no 
requirement for screening..  
 
An alternative method for ascertaining HPA function would have been the use of 
salivary cortisol.  Salivary cortisol secretion is a reliable indicator of free cortisol in 
plasma and salivary cortisol levels have been correlated with serum and 24-hour 
urine cortisol levels in children and adults. Cortisol secretion follows a daily circadian 
rhythm with a daily peat between 5am and 8am and lowest levels around midnight. 
Therefore, a single salivary cortisol collected at a standardised time of day for all 
participants would have been a less invasive method of determining HPA function. 





2. Hypothalamic-pituitary-Gonadal Axis 
Nearly one-third (28.1%) of male participants in our cohort had low serum 
testosterone levels. Suppression of the hypothalamic–pituitary–gonadal axis is 
common after TBI and stress. It is thought that a decrease in the sex hormone 
pathways during stress is an adaptive means of energy conservation to deal with the 
acute stressor.  A high prevalence of gonadotrophin deficiency has been reported for 
all severities of TBI, particularly in male participants. Low serum testosterone levels 
have been reported in up to 100% of male participants in the first few days following 
injury27 28. The degree of testosterone suppression correlates with injury severity, 
however in our cohort, there was no difference between participants with and without 
complex mTBIs. The significance of low testosterone levels in patients that have 
sustained mTBI remains unclear, however, it has recently been shown that 
suppression of the gonadotrophin pathways may be associated with post-traumatic 
stress diagnosis (PTSD)29. Only one of the 9 male participants with low testosterone 
in the acute phase had a persistently low testosterone level after 6 months. Given, 
the potentially detrimental health consequences of gonadal suppression, male 
patients should be screened for low testosterone acutely following mTBI.  
3. Growth Hormone 
Of the 5 patients with abnormal levels of IGF-1, 4 had elevated levels of IGF-1 in the 
first week following mTBI. Most studies that have examined IGF-1 expression in the 
days following TBI have reported a reduction in serum IGF-1 concentration27 30 31 32. 
Most of these were studies that included participants with moderate and severe TBI. 
In vivo animal studies have shown a negative correlation between serum IGF-1 




conceivable that elevate IGF-1 levels following mTBI may be a neuroprotective 
adaptive response33. Only one patient in our cohort had low serum IGF-1, suggesting 
that routine IGF-1 screening is unnecessary acutely following mTBI. 
4. Thyroid and Prolactin 
Serum concentrations of prolactin and thyroid hormones can be affected by stress 
including TBI34 35. There are varying reports on the significance of these pathways in 
the acute stages of TBI36 37. Only one patient had biochemical evidence of 
hypothyroid and hyperprolactinaemia acutely and this was likely a consequence of 
the oral contraceptive pill which was undisclosed at the time of recruitment. We did 
not find that these hormones were significantly affected by mTBI and therefore there 
is no evidence for routine screening acutely following mTBI. 
 
Pituitary (dys)function at 6 months 
The reported incidence of chronic pituitary dysfunction also varies considerably in 
the literature. Tanriverdi and colleagues, in a 3-year, prospective study, reported that 
17% of 18 patients with mTBI in their cohort had PTPD. Of note, 15 of 18 patients 
(including all with PTPD) had complex mTBIs suggesting that patients with complex 
mTBI have a substantial risk38. By contrast, in the study by van der Eerden and 
colleagues, there was a low incidence of PTPD in patients who had stimulation 
testing a median of 13 months following mTBIs39. Only one patient was ultimately 
found to have evidence of anterior pituitary dysfunction representing less than 1% of 
patients followed up.. This study did not take into consideration the propensity for de 




function had previously been normal. Only patients with abnormal anterior pituitary 
baseline screening were followed up with stimulation tests month after their initial 
TBI. It is therefore likely that this study underestimated the prevalence of PTPD.  
In our cohort, we found that 20% of the returning patients had PTPD at 6 months. 
Although the proportion of returning patients was small, this corresponds with the 
prevalence of PTPD reported in the three systematic reviews that have been written 
on the topic4 10 11.  It is noteworthy that in our systemic review there was no statistical 
difference between the studies that had high proportions (>50%) of participants with 
mTBI and those with low proportions (<50%) of participants with mTBI. It therefore 
seems appropriate to conclude that a proportion of patients with mTBI go on to 
develop abnormal pituitary function months following mTBI. 
 
The anterior pituitary response to mTBI: Pathogenesis of PTPD 
Formulating a hypothesis on the pathogenesis of PTPD is relies on a clear 
understanding of the how the brain and the anterior pituitary gland responds to 
trauma and our study provides some insight. There are three main theories. Firstly, 
the vascular hypothesis proposes that the long hypophyseal vessels that supply the 
pituitary gland are particularly vulnerable to injury and since the anterior lobe of the 
pituitary gland receives its blood supply from these vessels, hormone dysfunction 
following trauma results from vascular compromise40 41. Secondly, the autoimmunity 
hypothesis suggests that the pituitary may be infiltrated by inflammatory cells 
released in response to or because of trauma42. Thirdly, the neuroendocrine theory 
suggests that altered hypothalamo-pituitary function caused by the impact of trauma 





We have shown that anterior pituitary hormonal dysfunction, which is well 
documented in more severe forms of TBI, occurs in the first few days following mTBI 
and that this abnormal serum anterior pituitary biochemistry occurs without structural 
damage to the pituitary gland and without evidence of haemorrhage, necrosis, 
inflammation or ischaemic changes in the anterior pituitary gland. The biochemical 
result is an increase in potentially neuroprotective hormones (cortisol and IGF-1) and 
suppression in others (testosterone). This adaptive response is clearly selective as it 
is not proportional to the volume of the different cell types of the anterior pituitary. 
Approximately 50% of the cells of the anterior pituitary are somatotrophs that 
produce growth hormone (GH) and the prolactin-secreting lactotrophs and the 
corticotrophs each represent approximately 15% of cells. Gonadotroph cells 
represent only approximately 10% of the human anterior pituitary cell population and 
thyrotrophs are the least abundant cell type in the anterior pituitary, comprising 
approximately 5% of the total cell population. In our cohort gonadotrophin, 
somatotroph and corticotroph abnormalities were the most common. This suggests 
that the adaptive response of the anterior pituitary selectively involves these cell 
types. The precise mechanisms involved are still uncertain. A prospective, large and 
multi-centre study, perhaps with a higher resolution MRI imaging of the pituitary 
gland, is needed for a better insight of the pathogenesis of PTPD. 
Study limitations 
This study was conducted as a feasibility study with two main limitations. Firstly, only 
two-thirds of recruited patients retuned for initial blood tests and only 50% of the 




highlights the difficulties of researching this group of patients who are typically young 
and in employment and therefore struggle to return for appointments. Secondly, not 
all patients received an MRI scan. MRI imaging for all patients would have added to 
the breadth of understanding of the morphological changes that may occur in the 
pituitary gland following mTBI. This study is also limited by the fact that only single 
basal hormone levels were assessed. Although pragmatic, single blood tests do not 
reflect the pulsatile secretory pattern of some anterior pituitary hormones. Finally, we 
did not perform stimulation tests acutely because of the documented risk of seizures, 




Despite these limitations, we have demonstrated that the anterior pituitary’s adaptive 
response to mTBI leads to over-activity in the acute stages of trauma leading to 
increased hormone production. We have also shown that PTPD, which is typically 
thought to affect patients with moderate and severe TBIs, also occur in patients with 
mTBI and surveillance guidelines in the future should take this into account. Despite 
this, there was a high rate of attrition in line with the well-known difficulties in follow-
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We showed in this feasibility study that the study protocol is workable and also found 
that some patients with mild TBI develop chronic anterior pituitary dysfunction. The 








Should we check for anterior pituitary dysfunction in all traumatic brain injury 
patients? 
• What you need to know? 
• There is uncertainty about the clinical significance of post-traumatic brain 
injury anterior pituitary dysfunction (PTPD) 
• Studies suggest that up to one-third of patients that suffer traumatic brain 
injury (TBI) go on to develop anterior pituitary gland dysfunction but these 
studies are heterogeneous, use different methodologies and mostly recruit 
patients with the most severe forms of TBI Anterior pituitary dysfunction can 
be very difficult to diagnose in these patients. There should be a high index of 
suspicion particularly for patients with ongoing behavioural, mood and 
cognitive disturbances 
• Patients with base of skull fractures should be considered at high risk of 
developing pituitary dysfunction 
 
Acute imbalances of anterior pituitary gland hormones occur commonly in the first 
few days after traumatic brain injury (TBI). They usually resolve. Some patients 
develop long-term anterior pituitary dysfunction (3 or more months after TBI). Three 
meta-analyses have concluded that up to one-third of patients that suffer TBI go on 




TBI has been described as a “silent epidemic”, and is one of the most common 
causes of death and disability in people under 40 years old4. Given the scale of TBI, 
this could make TBI the most common cause of anterior pituitary dysfunction. As 
anterior pituitary dysfunction is relatively easy to treat with hormone replacement, 
diagnosing and treating affected individuals is an important therapeutic intervention 
in the rehabilitation of TBI sufferers, many of whom never return to their pre-morbid 
function because of ongoing cognitive and neuropsychological problems5. 
 
What is the evidence of uncertainty? 
Search strategy 
We searched PubMed and the Cochrane Library for observational studies and 
randomised control trials of anterior pituitary dysfunction following TBI33. There is 
evidence that anterior pituitary dysfunction in these patients is dynamic up to a year 
after TBI: with resolution in some patients that develop pituitary dysfunction within a 
few months after TBI and late, de novo dysfunction, several months after injury in 
patients whose anterior pituitary had previously been normal. We therefore only 
included papers that tested pituitary dysfunction in adults (>17 years) on average a 
year or more following TBI. The Newcastle-Ottawa scale (NOS) was used to 
determine study quality. Studies that scored 8 or more were deemed to be at low risk 







What proportion of patients develop PTPD? 
Our literature search identified 29 studies of which 17 were deemed to be at high risk 
of bias6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 and 12 were low risk of bias23 24 25 26 27 28 29 30 
31 32 33 34. The overall prevalence of PTPD for the 12 studies at low risk of bias was 
35% (fixed and random effect model) and the overall prevalence for the studies at 
high risk of bias was 28% (figure 1). The overall prevalence for all 29 studies was 
29.1% [95% confidence interval 23.6% - 35.4%; I2 89.2%]. There was considerable 
bias in the included studies. Most studies focused on patients with moderate and 
severe TBI (which form 10-20% of TBIs) that were mostly recruited from intensive 
care units and endocrinology clinics and the results may not be generalisable to the 
much larger mild TBI population. Also, the methods used to assess anterior pituitary 
function, particularly growth hormone and adrenocorticotrophin function, varied 
between studies. 
When is the best time to check for PTPD? 
The recent screening guidelines by the British Neurotrauma Group recommended 
that evidence of PTPD should be checked at 3-6 months following TBI if patients 
were initially admitted to hospital for more than 48 hours or if they experience 
symptoms suggestive of pituitary dysfunction35. This guidance, based on expert 
opinion, is one of the most extensive currently available. These recommendations 
take into account the observation that chronic anterior PTPD is a dynamic process, 
which can spontaneously resolve in some patients but also importantly that can 
develop late in others some months following TBI even if earlier testing for anterior 
PTPD had previously been negative. Of the 29 included studies included in our 




after TBI, and 2 reported on its prevalence at 6 months and at 9 months after TBI. A 
boxplot of the overall prevalence at these time intervals is depicted in figure 2. The 
overall prevalence of PTPD at 3 months was 34.1% [95% CI 24.6-44.9%; I2 78.7%], 
the overall prevalence at 6 months was 26.4% [95% CI 15.2 – 41.7%; I2 70%], the 
overall prevalence at 9 months was 23.4% [95% CI 17.1%-31.1%; I2 0%]. Although 
there were no statistical differences in the overall prevalence between the groups, 
these figures seem to endorse the theory that resolution occurs in some patients 
over time (although the mechanism is unclear) and the increase in prevalence 
between 9 months (23%) and 12 months (35%) suggests that some patients develop 
late, de novo PTPD. The clinical implication, as highlighted in the British 
Neurotrauma group guidelines, is that early surveillance alone might miss some 
patients that develop late PTPD.  
The criticism of the British Neurotrauma group guidelines, which the authors 
themselves noted, is that the symptoms of pituitary dysfunction overlap with those of 
post-concussion syndrome and it may be difficult to stratify suitability for screening 
on symptoms alone at 12 months or more. 
 
What are the current surveillance practices amongst Neurosurgeons in the UK 
and Ireland? 
In a survey of 45 Surgeons in England, Scotland and Ireland, the majority of 
participants (86.7%) considered PTPD to be a problem but only 25% (11/45) 




determine which patients were screened. This suggests that even amongst experts, 
there are disparities in surveillance practices across the UK. 
What are the risk factors for chronic anterior PTPD? 
It is important to consider potential risk factors for chronic anterior PTPD in order to 
better determine which patients should be screened. Six of the 29 authors included 
in the meta-analysis reported on the risk factors for developing PTPD6 16 19 26 28 32. In 
addition, we found 2 further studies that followed patients up for 9 months (both with 
a NOS score of 8) that reported on risk factors for chronic anterior PTPD36 37. We 
pooled the results of eight potential risk factors reported by the majority of these 
studies for the overall risk of developing PTPD. These risk factors included: 
1. abnormal pupils at the time of TBI;  
2. brain swelling on neuroimaging;  
3. presence of cranial vault or facial fractures,  
4. pre-resuscitation hypoxia or hypotension,  
5. male gender,  
6. mild TBI vs. non mild TBI,  
7. moderate or severe TBI vs. non moderate or severe TBI and  
8. presence of subarachnoid blood on neuroimaging.  
Only the presence of fractures was significantly associated with the development of 
chronic anterior PTPD (RR 1.52[95% CI 1.03-2.24];p=0.03) (figure 3). However, we 
recently completed a study in which 36 participants with mild TBI were followed up 




evidence of PTPD without any structural damage to their pituitary gland on MRI scan 
(unpublished). This suggests that patients with mild TBIs are also at risk. 
 
What should we do in light of this research? 
Ideally, all TBI sufferers should be screened for PTPD. However, this would be both 
costly and logistically difficult as follow up in this patient group38. In the absence of 
level one evidence, there has to be a pragmatic approach to surveillance. Firstly, 
chronic anterior PTPD should be borne in mind when dealing with patients who 
progress slowly during rehabilitation from TBI. Pituitary testing should be considered 
early (3 to 6 months) and late (at least 12 months) in these patients and in those that 
have symptoms suggestive of pituitary dysfunction. We recommend the surveillance 
algorithm of British Neurotrauma Group (figure 4) and would suggest that those with 
base of skull fractures may be at increased risk. 
Screening blood tests should be done between 8am and 10am and should be done 
with the patient fasted (nothing to eat from midnight on the day of testing) unless 
contraindicated. The following blood tests should be done in all patients suspected of 
having PTPD: 
- TSH and free T4 
- Short-synacthen test (SST) or early morning cortisol, if SST not feasible  
In addition, men and post-menopausal women should have their gonadotropic axis 
tested (including luteinising hormone (LH), follicle-stimulating hormone (FSH), 




with regular menstrual cycles do not need an assessment of their gonadotropic axis. 
Posterior pituitary dysfunction may be assessed initially by asking about symptoms 
of thirst, polydipsia and polyuria. 
Screening for somatotropic axis dysfunction (growth hormone) is more challenging; 
formal testing can be lengthy and in the case of insulin tolerance testing, be 
contraindicated in some patients with TBI. We would therefore suggest that patients 
suspected of having anterior pituitary dysfunction and in whom the above tests are 












Recommendations for Future Research 
Population 
• Patients with mild TBI recruited from A&E as well as those with moderate 
and severe TBI. 
Intervention 
• Patients should be followed up prospectively for at least 12 months and 
stimulation tests should be used to test growth hormone and 
adrenocorticotrophin axes, when safe to do so  
Comparisons 
• hormone replacement therapy, particularly growth hormone and 
testosterone replacement, following TBI should also be considered. 
Outcomes 
• risk factors for developing PTPD including patient factors and injury factors  
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Figure 2. Forest plot of pooled proportions (and 95% confidence intervals [CI]) of anterior 
pituitary dysfunction one year or more following traumatic brain injury. Studies were 
separated into high and low quality based on the Newcastle-Ottawa score (NOS), which 
assesses the quality of non-randomised studies. The square boxes represent the reported 
prevalence for each study and whiskers represent 95% confidence interval. The diamonds 
represent the pooled proportions. Pooled proportions were calculated using 2 models. The 
large diamonds represent pooled proportions calculated with random effect model and the 


















Figure 3. Forest plot of pooled risk ratios for reported risk factors for developing post-TBI 
anterior pituitary dysfunction. The solid circles are the risk ratios and the whiskers are the 
95% confidence intervals (95%CI). Only the presence of fracture (cranial or facial) 











Figure 4. Recommendations for screening for pituitary dysfunction in patients with 






In this thesis, I conducted a systematic review that demonstrated evidence for anterior 
pituitary dysfunction following traumatic brain injury and a questionnaire that indicated 
variations in surveillance practices across the UK and Ireland. This suggested that 
there were uncertainties about the burden of disease. I therefore designed a study to 
address the research question “what is the prevalence of anterior pituitary dysfunction 
following traumatic brain injury?” and conducted a feasibility study to test all aspects of 
the study protocol. Whilst these objectives were met, there were problems along the 
way. These problems are listed here. 
  
1. Defining anterior pituitary dysfunction 
The definition of anterior pituitary dysfunction is unreliable when based solely on the 
serum concentrations of anterior pituitary hormones alone and in the absence of a pre-
test probability of anterior pituitary hormone deficiency. This is because several factors 
including the physiological response to stress and trauma, seizures and some 
medications influence anterior pituitary hormone secretion. One solution to this 
problem could have been to have a control group of non-TBI trauma patients to 
compare anterior pituitary function. However, this would have been difficult to achieve 
with the resources available and may have been unreliable if a significant proportion of 
the control group were also found to have pituitary dysfunction. A second solution 
would have been to follow patients up in an endocrinology clinic with the involvement 
of an endocrinologist to determine each participant’s pre-test probability of anterior 
pituitary dysfunction prior to blood test. Although an endocrinologist was involved in 






2. Sampling bias 
The patients recruited to the PiTS study were those who presented to the emergency 
department. We also recruited patients being admitted to a single centre for the 
feasibility study. The majority of patients with mild TBI do not come to hospital and 
therefore would not be included in the PitSTOP study. The results are therefore not 
generalisable to mild TBI patients. I have dealt with this problem in the study my 
assuming that patients with the most ‘severe’ forms of mild TBI (in this case, those that 
meet the NICE guidelines for brain imaging) are at higher risk of developing pituitary 
dysfunction. Although there is currently no evidence for this assumption, it was a 
pragmatic solution as it would be difficult to obtain a population-based sample of 
patients with TBIs that are managed in the primary care setting or who do not attend 
hospital. 
 
3. Sampling size and recruitment 
Patient recruitment was difficult because for two reasons. Firstly, patients tended to 
present out of hours and we initially had no research support out of hours. Therefore, a 
large number of potential patients were missed during their hospital stay and not 
approached for inclusion. This was dealt with by changing the working patterns of 
members of the research team. The second problem was the very high proportion of 
patients who having consented for inclusion, failed to attend subsequent visits. 
Although we tried to reduce the burden on patients by reducing the number of visits, 
only approximately 56% of recruited patient came to the first visit and 28% attended 




limited resources, however one solution for future studies would be to incentivise 
patients financially or otherwise to attend research visits. 
 
4. Data Collection and Lab interaction 
Because the study team was small, we relied on the clinical and nursing staff to record 
participants’ observations. However, we found that as many of the participants recruited to 
this study were generally well, many did not get a full set of clinical observations recorded 
and therefore missing data was picked up on a number of occasions by the trial team. This 
included discharge data such as discharge destination and sample times not being 
completed. 
 
We also found that early on in the study blood samples were often mislabelled or were not 
completed because the clinical staff or the laboratory staff were unaware of the study. This 
resulted in a frustrating number of uncompleted sampling for patients who ultimately could 
not be included in the final analysis. 
 
These problems were resolved by meetings which were organised to provide better 
information to all stakeholders including the clinical and nursing staff and the laboratory 
staff to ensure all were aware of the study. Due to the time critical nature of the study, we 
highlighted the need to prioritise and coordinate the recruitment process efficiently. 
Therefore, working with the multidisciplinary team closely was vital to capture patients 






We also developed techniques to ensure all data was captured to complete the CRF. For 
example, alert cards were placed in patient notes to alert the clinician to complete the 
clinician assessment. 
 
5. Future directions 
Despite the limitations, I was able to design and conduct, prospectively, a study which has 
shown that anterior pituitary dysfunction occurs in patients following mild TBI. I have also 
been able to prove that the PitSTOP protocol is workable and therefore the next stage is to 
apply for funding for the PitSTOP study. There are three main questions that need to be 
addressed: 
1. How common is chronic anterior pituitary dysfunction following TBI? 
2. Which TBI patients are at risk of developing anterior pituitary dysfunction? 
3. What surveillance methods should be used to detect such patients? 
 
A large prospective study using the PitSTOP protocol will answer these questions. Given 
that anterior pituitary dysfunction is potentially treatable with hormone replacement, this 
could represent a significant study in TBI research. 
 
